

Reference List

1. Aalto J, Kiianmaa K. Role of brain monoaminergic systems in the increased ethanol drinking caused by REM-sleep deprivation. *Alcohol Alcohol*. 1987;Suppl 1:313-317.
2. Adell A, Celada P, Abellan MT et al. Origin and functional role of the extracellular serotonin in the midbrain raphe nuclei. *Brain Res Brain Res Rev*. 2002;39:154-180.
3. Adrien J, Tissier MH, Lanfumey L et al. Central action of 5-HT₃ receptor ligands in the regulation of sleep-wakefulness and raphe neuronal activity in the rat. *Neuropharmacology*. 1992;31:519-529.
4. Adrien J, Laguzzi R, Bourgoïn S et al. [Sleep in the rat following raphe lesion: pharmacology of the serotonin system]. *Waking Sleeping*. 1980;4:119-129.
5. Adrien J. Ontogenesis of some sleep regulations: early postnatal impairment of the monoaminergic systems. *Prog Brain Res*. 1978;48:393-405.
6. Adrien J. [Sleep organisation in the kitten following early lesions to the structures involved in the regulation of alertness (author's trans)]. *Rev Electroencephalogr Neurophysiol Clin*. 1977;7:278-283.
7. Adrien J, Bourgoïn S, Hamon M. Midbrain raphe lesion in the newborn rat I. Neurophysiological aspects of sleep. *Brain Res*. 1977;127:99-110.
8. Albert R, Merz A, Schubert J et al. [Sleep deprivation and subsequent sleep phase advance stabilizes the positive effect of sleep deprivation in depressive episodes]. *Nervenarzt*. 1998;69:66-69.
9. Arita H, Ichikawa K, Sakamoto M. Serotonergic cells in nucleus raphe pallidus provide tonic drive to posterior cricoarytenoid motoneurons via 5-hydroxytryptamine₂ receptors in cats. *Neurosci Lett*. 1995;197:113-116.
10. Ashley DV. Dietary control of brain 5-hydroxytryptamine synthesis: implications in the etiology of obesity. *Int J Vitam Nutr Res Suppl*. 1986;29:27-40.
11. Asikainen M, Toppila J, Alanko L et al. Sleep deprivation increases brain serotonin turnover in the rat. *Neuroreport*. 1997;8:1577-1582.
12. Barratt ES, Adams PM, Poffenbarger PL et al. Effects of rapid depletion of phenylalanine and tyrosine on sleep and behavior. *Pharmacol Biochem Behav*. 1976;5:47-53.
13. Bender DA. Biochemistry of tryptophan in health and disease. *Mol Aspects Med*. 1983;6:101-197.
14. Bjorkum AA, Bjorvatn B, Neckelmann D et al. Sleep effects following intrathecal administration of the 5-HT_{1A} agonist 8-OH-DPAT and the NMDA antagonist AP-5 in rats. *Brain Res*. 1995;692:251-258.
15. Bjorvatn B, Gronli J, Hamre F et al. Effects of sleep deprivation on extracellular serotonin in hippocampus and frontal cortex of the rat. *Neuroscience*. 2002;113:323-330.
16. Blois R, Feinberg I, Gaillard JM et al. Sleep in normal and pathological aging. *Experientia*. 1983;39:551-558.
17. Bobrzynska KJ, Godfrey MH, Mrosovsky N. Serotonergic stimulation and nonphotic phase-shifting in hamsters. *Physiol Behav*. 1996;59:221-230.
18. Bonard EC. [Tryptophan and serotonin]. *Rev Med Suisse Romande*. 1987;107:701-702.
19. Borbely AA. [Physiological and pharmacological study of the regulation of sleep in rats]. *Actual Pharmacol (Paris)*. 1981;33:91-104.

20. Borbely AA. Effects of light on sleep and activity rhythms. *Prog Neurobiol.* 1978;10:1-31.
21. Bouhuys AL, Van Den Hoofdakker RH. Effects of midbrain raphe destruction on sleep and locomotor activity in rats. *Physiol Behav.* 1977;19:535-541.
22. Brown DW. Abnormal fluctuations of acetylcholine and serotonin. *Med Hypotheses.* 1993;40:309-310.
23. Bucci L. Migraine, insomnia, reactive depression due to brain serotonin deficiency. *Br J Psychiatry.* 1988;152:867-868.
24. Carchedi F, Di Ceglie M, Casacchia M et al. [Sleep: biochemical correlations and pharmacological considerations]. *Clin Ter.* 1979;91:3-10.
25. Carley DW, Radulovacki M. Role of peripheral serotonin in the regulation of central sleep apneas in rats. *Chest.* 1999;115:1397-1401.
26. Curzon G. The role and control of brain 5-hydroxytryptamine. *Acta Neurol (Napoli).* 1977;32:121-131.
27. Drucker-Colin RR, Spanis CW. Is there a sleep transmitter? *Prog Neurobiol.* 1976;6:1-22.
28. Dugovic C. Role of serotonin in sleep mechanisms. *Rev Neurol (Paris).* 2001;157:S16-S19.
29. Fenik P, Ogawa H, Veasey SC. Hypoglossal nerve response to 5-HT₃ drugs injected into the XII nucleus and vena cava in the rat. *Sleep.* 2001;24:871-878.
30. Fornal C, Radulovacki M. Sleep suppressant action of fenfluramine in rats. I. Relation to postsynaptic serotonergic stimulation. *J Pharmacol Exp Ther.* 1983;225:667-674.
31. Guilleminault C. Advances in the pathology of sleep. *Electroencephalogr Clin Neurophysiol Suppl.* 1978;67-70.
32. Gursky JT, Krahn LE. The effects of antidepressants on sleep: a review. *Harv Rev Psychiatry.* 2000;8:298-306.
33. Harding SM. Sleep in fibromyalgia patients: subjective and objective findings. *Am J Med Sci.* 1998;315:367-376.
34. Hartmann E. L-tryptophan: a rational hypnotic with clinical potential. *Am J Psychiatry.* 1977;134:366-370.
35. Hilakivi I. Biogenic amines in the regulation of wakefulness and sleep. *Med Biol.* 1987;65:97-104.
36. Hobson JA. Sleep and dreaming: induction and mediation of REM sleep by cholinergic mechanisms. *Curr Opin Neurobiol.* 1992;2:759-763.
37. Holmes CJ, Jones BE. Importance of cholinergic, GABAergic, serotonergic and other neurons in the medial medullary reticular formation for sleep-wake states studied by cytotoxic lesions in the cat. *Neuroscience.* 1994;62:1179-1200.
38. Holsboer F. Serotonin and sleep regulation. *Clin Neuropharmacol.* 1992;15 Suppl 1 Pt A:349A-350A.
39. Janzen R, Hunger J. [Causes of sleep disorders from the viewpoint of the neurologist]. *Internist (Berl).* 1976;17:232-238.
40. Jouvet M. Sleep and serotonin: an unfinished story. *Neuropsychopharmacology.* 1999;21:24S-27S.
41. Karnovsky ML. Progress in sleep. *N Engl J Med.* 1986;315:1026-1028.
42. Kayama Y, Koyama Y. [Brainstem neural mechanisms of sleep and wakefulness]. *Nippon Seirigaku Zasshi.* 1993;55:1-14.

43. Koyama Y, Kayama Y, Sakai K. [Neural mechanisms for sleep regulation]. *Nippon Rinsho*. 1998;56:318-326.
44. Lanoir J, Ternaux JP, Pons C et al. Long-term effects of a tryptophan-free diet on serotonin metabolism and sleep-waking balance in rats. *Exp Brain Res*. 1981;41:346-357.
45. Leathwood PD. Tryptophan availability and serotonin synthesis. *Proc Nutr Soc*. 1987;46:143-156.
46. Leathwood PD. Neurotransmitter precursors and brain function. *Bibl Nutr Dieta*. 1986;54-71.
47. Leonard BE. Serotonin receptors and their function in sleep, anxiety disorders and depression. *Psychother Psychosom*. 1996;65:66-75.
48. Lydic R, McCarley RW, Hobson JA. Serotonin neurons and sleep. II. Time course of dorsal raphe discharge, PGO waves, and behavioral states. *Arch Ital Biol*. 1987;126:1-28.
49. Lydic R, McCarley RW, Hobson JA. Serotonin neurons and sleep. I. Long term recordings of dorsal raphe discharge frequency and PGO waves. *Arch Ital Biol*. 1987;125:317-343.
50. McGinty D, Szymusiak R. The sleep-wake switch: A neuronal alarm clock. *Nat Med*. 2000;6:510-511.
51. Mendelson WB. Neurotransmitters and sleep. *J Clin Psychiatry*. 2001;62 Suppl 10:5-8.
52. Morgane PJ. Amine pathways and sleep regulation. *Brain Res Bull*. 1982;9:743-749.
53. Morgane PJ, Stern WC. The role of serotonin and norepinephrine in sleep-waking activity. *Natl Inst Drug Abuse Res Monogr Ser*. 1975;37-61.
54. Sallanon M, Janin M, Buda C et al. Serotonergic mechanisms and sleep rebound. *Brain Res*. 1983;268:95-104.
55. Wauquier A, Dugovic C. Serotonin and sleep-wakefulness. *Ann N Y Acad Sci*. 1990;600:447-458.
56. Webb SM. Fibromyalgia and melatonin: are they related? *Clin Endocrinol (Oxf)*. 1998;49:161-162.
57. Wesemann W, Rotsch M, Schulz E et al. Circadian rhythm of serotonin binding in rat brain--II. Influence of sleep deprivation and imipramine. *Chronobiol Int*. 1986;3:141-146.
58. Fernstrom JD, Wurtman RJ. Control of brain serotonin levels by the diet. *Adv Biochem Psychopharmacol*. 1974;11:133-142.
59. Fernstrom JD, Wurtman RJ. Brain serotonin content: physiological dependence on plasma tryptophan levels. *Science*. 1971;173:149-152.
60. Madras BK, Cohen EL, Fernstrom JD et al. Letter: Dietary carbohydrate increases brain tryptophan and decreases free plasma tryptophan. *Nature*. 1973;244:34-35.
61. Wurtman RJ. When--and why--should nutritional state control neurotransmitter synthesis? *J Neural Transm Suppl*. 1979;69-79.
62. Wurtman RJ. Nutrients affecting brain composition and behavior. *Integr Psychiatry*. 1987;5:226-238.
63. Airapetyants MG, Hecht K, Mekhedova AY et al. Effect of intermittent hypokinesia of varied duration on conditioned reflexes, the EEG, and blood neurotransmitter levels in rats. *Neurosci Behav Physiol*. 1982;12:154-161.
64. Amatruda TT, III, Black DA, McKenna TM et al. Sleep cycle control and cholinergic mechanisms: differential effects of carbachol injections at pontine brain stem sites. *Brain Res*. 1975;98:501-515.
65. Baust W, Otter HP. Studies on the cholinergic system of the reticular formation. *Electroencephalogr Clin Neurophysiol*. 1969;27:675.

66. Borsook D, Richardson GS, Moore-Ede MC et al. GABA and circadian timekeeping: implications for manic-depression and sleep disorders. *Med Hypotheses*. 1986;19:185-198.
67. Bowers MB, Jr., Hartmann EL, Freedman DX. Sleep deprivation and brain acetylcholine. *Science*. 1966;153:1416-1417.
68. Brown DW. Abnormal fluctuations of acetylcholine and serotonin. *Med Hypotheses*. 1993;40:309-310.
69. Carchedi F, Di Ceglie M, Casacchia M et al. [Sleep: biochemical correlations and pharmacological considerations]. *Clin Ter*. 1979;91:3-10.
70. Chumakova OV, Liopo AV. Acetylcholinesterase and choline uptake in striatum from rats with varying sleeping times. *Alcohol Alcohol*. 1996;31:217-220.
71. Cudeiro J, Rivadulla C, Grieve KL. A possible role for nitric oxide at the sleep/wake interface. *Sleep*. 2000;23:829-835.
72. Datta S, Calvo JM, Quattrochi J et al. Cholinergic microstimulation of the peribrachial nucleus in the cat. I. Immediate and prolonged increases in ponto-geniculo-occipital waves. *Arch Ital Biol*. 1992;130:263-284.
73. De Souza H, Neto JP. Effects of anti-acetylcholine drugs on aggressive behaviour induced by Cannabis sativa in REM sleep-deprived rats. *J Pharm Pharmacol*. 1978;30:591-592.
74. Gadea-Ciria M, Stadler H, Lloyd KG et al. Acetylcholine release within the cat striatum during the sleep-wakefulness cycle. *Nature*. 1973;243:518-519.
75. Gaillard JM. Neurochemical regulation of the states of alertness. *Ann Clin Res*. 1985;17:175-184.
76. Gillin JC, Mendelson WB, Sitaram N et al. The neuropharmacology of sleep and wakefulness. *Annu Rev Pharmacol Toxicol*. 1978;18:563-579.
77. Gillin JC, Sitaram N. Rapid eye movement (REM) sleep: cholinergic mechanisms. *Psychol Med*. 1984;14:501-506.
78. Gillin JC, Mendelson WB, Sitaram N et al. The neuropharmacology of sleep and wakefulness. *Annu Rev Pharmacol Toxicol*. 1978;18:563-579.
79. Graves L, Pack A, Abel T. Sleep and memory: a molecular perspective. *Trends Neurosci*. 2001;24:237-243.
80. Haranath PS, Venkatakrishna-Bhatt H. Release of acetylcholine from perfused cerebral ventricles in unanaesthetized dogs during waking and sleep. *Jpn J Physiol*. 1973;23:241-250.
81. Hernandez-Peon R, O'Flaherty JJ, Mazzuchelli O'F. Sleep and other behavioural effects induced by acetylcholinic stimulation of basal temporal cortex and striate structures. *Brain Res*. 1967;4:243-267.
82. Hilakivi I. Biogenic amines in the regulation of wakefulness and sleep. *Med Biol*. 1987;65:97-104.
83. Hobson JA, Datta S, Calvo JM et al. Acetylcholine as a brain state modulator: triggering and long-term regulation of REM sleep. *Prog Brain Res*. 1993;98:389-404.
84. Kayama Y, Koyama Y. Brainstem neural mechanisms of sleep and wakefulness. *Eur Urol*. 1998;33 Suppl 3:12-15.
85. Koella WP. The organization and regulation of sleep. A review of the experimental evidence and a novel integrated model of the organizing and regulating apparatus. *Experientia*. 1984;40:309-338.
86. Koyama Y, Kayama Y, Sakai K. [Neural mechanisms for sleep regulation]. *Nippon Rinsho*. 1998;56:318-326.
87. Masserano JM, King C. Effects on sleep of acetylcholine perfusion of the locus coeruleus of cats. *Neuropharmacology*. 1982;21:1163-1167.

88. McGinty DJ, Drucker-Colin RR. Sleep mechanisms: biology and control of REM sleep. *Int Rev Neurobiol.* 1982;23:391-436.
89. Mendelson WB. Neurotransmitters and sleep. *J Clin Psychiatry.* 2001;62 Suppl 10:5-8.
90. Monnier M, Gaillard JM. Biochemical regulation of sleep. *Experientia.* 1980;36:21-24.
91. Nelson SR, Walaszek EJ. Pharmacology of the central nervous system. *Prog Neurol Psychiatry.* 1969;24:131-152.
92. Otter HP, Baust W. Experiments on cholinergic mechanisms for the control of tonic and phasic components of REM sleep. *Electroencephalogr Clin Neurophysiol.* 1970;29:218.
93. Perry E, Walker M, Grace J et al. Acetylcholine in mind: a neurotransmitter correlate of consciousness? *Trends Neurosci.* 1999;22:273-280.
94. Richter D. Biochemical changes during sleep. *Verh Dtsch Ges Inn Med.* 1965;71:819-826.
95. Rojas-Ramirez JA, Drucker-Colin RR. Sleep induced by spinal cord cholinergic stimulation. *Int J Neurosci.* 1973;5:215-221.
96. Saito Y. The circadian rhythm of brain acetylcholine levels and motor activity in the rat. *Life Sci I.* 1971;10:735-744.
97. Shiromani PJ, Kilduff TS, Bloom FE et al. Cholinergically induced REM sleep triggers Fos-like immunoreactivity in dorsolateral pontine regions associated with REM sleep. *Brain Res.* 1992;580:351-357.
98. Sitaram N, Nurnberger JI, Jr., Gershon ES et al. Cholinergic regulation of mood and REM sleep: potential model and marker of vulnerability to affective disorder. *Am J Psychiatry.* 1982;139:571-576.
99. Sitaram N, Wyatt RJ, Dawson S et al. REM sleep induction by physostigmine infusion during sleep. *Science.* 1976;191:1281-1283.
100. Steriade M. Cholinergic blockage of network- and intrinsically generated slow oscillations promotes waking and REM sleep activity patterns in thalamic and cortical neurons. *Prog Brain Res.* 1993;98:345-355.
101. Szymusiak R, Danowski J, McGinty D. REM sleep-suppressing effects of atropine in cats vary with environmental temperature. *Brain Res.* 1994;636:115-118.
102. Vazquez J, Baghdoyan HA. Basal forebrain acetylcholine release during REM sleep is significantly greater than during waking. *Am J Physiol Regul Integr Comp Physiol.* 2001;280:R598-R601.
103. Velazquez-Moctezuma J, Shiromani PJ, Gillin JC. Acetylcholine and acetylcholine receptor subtypes in REM sleep generation. *Prog Brain Res.* 1990;84:407-413.
104. Woolf NJ. Cholinergic systems in mammalian brain and spinal cord. *Prog Neurobiol.* 1991;37:475-524.
105. Borsook D, Richardson GS, Moore-Ede MC et al. GABA and circadian timekeeping: implications for manic-depression and sleep disorders. *Med Hypotheses.* 1986;19:185-198.
106. Holmes CJ, Jones BE. Importance of cholinergic, GABAergic, serotonergic and other neurons in the medial medullary reticular formation for sleep-wake states studied by cytotoxic lesions in the cat. *Neuroscience.* 1994;62:1179-1200.
107. Lemoine P, Allain H. Induction of sleep. *Sleep.* 1996;19:S1-S6.
108. Mallick BN, Kaur S, Saxena RN. Interactions between cholinergic and GABAergic neurotransmitters in and around the locus coeruleus for the induction and maintenance of rapid eye movement sleep in rats. *Neuroscience.* 2001;104:467-485.

109. Maloney KJ, Mainville L, Jones BE. c-Fos expression in GABAergic, serotonergic, and other neurons of the pontomedullary reticular formation and raphe after paradoxical sleep deprivation and recovery. *J Neurosci*. 2000;20:4669-4679.
110. Nitz D, Siegel J. GABA release in the dorsal raphe nucleus: role in the control of REM sleep. *Am J Physiol*. 1997;273:R451-R455.
111. Nitz D, Siegel JM. GABA release in the locus coeruleus as a function of sleep/wake state. *Neuroscience*. 1997;78:795-801.
112. Nitz D, Siegel JM. GABA release in posterior hypothalamus across sleep-wake cycle. *Am J Physiol*. 1996;271:R1707-R1712.
113. Pavel S, Eisner C. A GABAergic habenulo-raphé pathway mediates both serotonergic and hypnogenic effects of vasotocin in cats. *Brain Res Bull*. 1984;13:623-627.
114. Stahmer SD. Pharmacodynamics of benzodiazepines. *S Afr Med J*. 1985;Suppl:14-22.
115. Stock G. [Mechanisms of falling asleep. (Possibility of drug therapy in sleep disorders--participation of monoaminergic and gabaergic systems in the sleep-waking cycle)]. *Arzneimittelforschung*. 1981;Suppl 27:15-17.
116. Torterolo P, Yamuy J, Sampogna S et al. GABAergic neurons of the cat dorsal raphe nucleus express c-fos during carbachol-induced active sleep. *Brain Res*. 2000;884:68-76.
117. Xi MC, Morales FR, Chase MH. Evidence that wakefulness and REM sleep are controlled by a GABAergic pontine mechanism. *J Neurophysiol*. 1999;82:2015-2019.
118. Katzung B. Basic and Clinical Pharmacology. 7th ed. Stamford, Conn: Appleton and Lange, 1998.
119. DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. *Curr Drug Targets*. 2000;1:25-58.
120. Nathan P. Can the cognitive enhancing effects of ginkgo biloba be explained by its pharmacology? *Med Hypotheses*. 2000;55:491-493.
121. Dinsmore ST. Treatment options for Alzheimer's disease. *J Am Osteopath Assoc*. 1999;99:S6-S8.
122. Ott BR, Owens NJ. Complementary and alternative medicines for Alzheimer's disease. *J Geriatr Psychiatry Neurol*. 1998;11:163-173.
123. Kristofikova Z, Klaschka J. In vitro effect of Ginkgo biloba extract (EGb 761) on the activity of presynaptic cholinergic nerve terminals in rat hippocampus. *Dement Geriatr Cogn Disord*. 1997;8:43-48.
124. Ramassamy C, Clostre F, Christen Y et al. Prevention by a Ginkgo biloba extract (GBE 761) of the dopaminergic neurotoxicity of MPTP. *J Pharm Pharmacol*. 1990;42:785-789.
125. The role of excitatory amino acids in the actions of abused drugs. *NIDA Res Monogr*. 1994;140:65-68.
126. Angel-Meza AR, Ramirez-Cortes L, Adame-Gonzalez IG et al. Cerebral GABA release and GAD activity in protein- and tryptophan- restricted rats during development. *Int J Dev Neurosci*. 2002;20:47-54.
127. Arrigoni E, Rainnie DG, McCarley RW et al. Adenosine-mediated presynaptic modulation of glutamatergic transmission in the laterodorsal tegmentum. *J Neurosci*. 2001;21:1076-1085.
128. Barbeito L, Cheramy A, Godeheu G et al. Glutamate Receptors of a Quisqualate-Kainate Subtype are Involved in the Presynaptic Regulation of Dopamine Release in the Cat Caudate Nucleus in vivo. *Eur J Neurosci*. 1990;2:304-311.
129. Belenikin MS, Baskin II, Palyulin VA et al. A new binding mode of competitive antagonists to metabotropic glutamate receptors exemplified by the mGluR1-receptor antagonist AIDA (RS- aminoindan-1,5-dicarboxylic acid). *Dokl Biochem Biophys*. 2002;384:131-135.

130. Breyse N, Baunez C, Spooren W et al. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. *J Neurosci*. 2002;22:5669-5678.
131. Car H, Oksztel R, Nadlewska A et al. NMDA receptor antagonists change behavioral activity of rats treated with (S)-4CPG. *Pol J Pharmacol*. 2001;53:331-339.
132. Chiang AS, Pszczolkowski MA, Liu HP et al. Ionotropic glutamate receptors mediate juvenile hormone synthesis in the cockroach, *Diploptera punctata*. *Insect Biochem Mol Biol*. 2002;32:669-678.
133. Dhami GK, Anborgh PH, Dale LB et al. Phosphorylation-independent regulation of metabotropic glutamate receptor signaling by G protein-coupled receptor kinase 2. *J Biol Chem*. 2002;277:25266-25272.
134. Diaz-Cabiale Z, Vivo M, del Arco A et al. Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. *Neurosci Lett*. 2002;324:154-158.
135. Doi A, Ishibashi H, Jinno S et al. Presynaptic inhibition of GABAergic miniature currents by metabotropic glutamate receptor in the rat CNS.
136. Fendt M, Schmid S. Metabotropic glutamate receptors are involved in amygdaloid plasticity. *Eur J Neurosci*. 2002;15:1535-1541.
137. Giuliano F, Rampin O, Allard J. Neurophysiology and pharmacology of female genital sexual response. *J Sex Marital Ther*. 2002;28 Suppl 1:101-121.
138. Grosshans DR, Clayton DA, Coultrap SJ et al. Analysis of glutamate receptor surface expression in acute hippocampal slices. *Sci STKE*. 2002;2002:L8.
139. Holscher C. Metabotropic glutamate receptors control gating of spike transmission in the hippocampus area CA1. *Pharmacol Biochem Behav*. 2002;73:307-316.
140. Huemmeke M, Eysel UT, Mittmann T. Metabotropic glutamate receptors mediate expression of LTP in slices of rat visual cortex. *Eur J Neurosci*. 2002;15:1641-1645.
141. Karlsson U, Sjodin J, Angeby MK et al. Glutamate-induced currents reveal three functionally distinct NMDA receptor populations in rat dorsal horn - effects of peripheral nerve lesion and inflammation. *Neuroscience*. 2002;112:861-868.
142. Katsurabayashi S, Kubota H, Wang ZM et al. cAMP-dependent presynaptic regulation of spontaneous glycinergic IPSCs in mechanically dissociated rat spinal cord neurons. *J Neurophysiol*. 2001;85:332-340.
143. Lee RK, Jimenez J, Cox AJ et al. Metabotropic glutamate receptors regulate APP processing in hippocampal neurons and cortical astrocytes derived from fetal rats. *Ann N Y Acad Sci*. 1996;777:338-343.
144. Leinekugel X, Khazipov R, Cannon R et al. Correlated bursts of activity in the neonatal hippocampus in vivo. *Science*. 2002;296:2049-2052.
145. Li W, Trexler EB, Massey SC. Glutamate receptors at rod bipolar ribbon synapses in the rabbit retina. *J Comp Neurol*. 2002;448:230-248.
146. Mao L, Wang JQ. Glutamate Cascade to cAMP Response Element-Binding Protein Phosphorylation in Cultured Striatal Neurons through Calcium-Coupled Group I Metabotropic Glutamate Receptors. *Mol Pharmacol*. 2002;62:473-484.
147. Martin-Ruiz R, Puig MV, Celada P et al. Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism. *J Neurosci*. 2001;21:9856-9866.
148. Meeker RB. Metabotropic and NMDA glutamate receptor interactions with osmotic stimuli in supraoptic neurons. *Pharmacol Biochem Behav*. 2002;73:475-484.

149. Moghaddam B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders. *Biol Psychiatry*. 2002;51:775-787.
150. Neugebauer V. Metabotropic glutamate receptors - important modulators of nociception and pain behavior. *Pain*. 2002;98:1-8.
151. Pisani A, Bonsi P, Catania MV et al. Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons. *J Neurosci*. 2002;22:6176-6185.
152. Schoepp DD. Metabotropic glutamate receptors. *Pharmacol Biochem Behav*. 2002;73:285-286.
153. Sevoz-Couche C, Maisonneuve B, Hamon M et al. Glutamate and NO mediation of the pressor response to 5-HT₃ receptor stimulation in the nucleus tractus solitarii. *Neuroreport*. 2002;13:837-841.
154. Suchak SK, Baloyianni NV, Perkinson MS et al. The 'glial' glutamate transporter, EAAT2 (Glt-1) accounts for high affinity glutamate uptake into adult rodent nerve endings. *J Neurochem*. 2003;84:522-532.
155. Ulus IH, Wurtman RJ. Metabotropic glutamate receptor agonists increase release of soluble amyloid precursor protein derivatives from rat brain cortical and hippocampal slices. *J Pharmacol Exp Ther*. 1997;281:149-154.
156. Wang G, Ding S, Yunokuchi K. Glutamate-induced increases in intracellular Ca²⁺ in cultured rat neocortical neurons. *Neuroreport*. 2002;13:1051-1056.
157. Chen JF, Moratalla R, Impagnatiello F et al. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. *Proc Natl Acad Sci U S A*. 2001;98:1970-1975.
158. Chen JF, Xu K, Petzer JP et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. *J Neurosci*. 2001;21:RC143.
159. Conlay LA, Conant JA, deBros F et al. Caffeine alters plasma adenosine levels. *Nature*. 1997;389:136.
160. Conlay LA, Evoniuk G, Wurtman RJ. Endogenous adenosine and hemorrhagic shock: effects of caffeine administration or caffeine withdrawal. *Proc Natl Acad Sci U S A*. 1988;85:4483-4485.
161. Dulloo AG, Seydoux J, Girardier L. Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase inhibition? *Metabolism*. 1992;41:1233-1241.
162. Dulloo AG, Seydoux J, Girardier L. Peripheral mechanisms of thermogenesis induced by ephedrine and caffeine in brown adipose tissue. *Int J Obes*. 1991;15:317-326.
163. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. *Annu Rev Neurosci*. 2001;24:31-55.
164. Evoniuk G, von Borstel RW, Wurtman RJ. Antagonism of the cardiovascular effects of adenosine by caffeine or 8- (p-sulfophenyl)theophylline. *J Pharmacol Exp Ther*. 1987;240:428-432.
165. Schwarzschild MA, Chen JF, Ascherio A. Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. *Neurology*. 2002;58:1154-1160.
166. Tofovic SP, Zacharia L, Carcillo JA et al. Inhibition of adenosine deaminase attenuates endotoxin-induced release of cytokines in vivo in rats. *Shock*. 2001;16:196-202.
167. von Borstel RW, Renshaw AA, Wurtman RJ. Adenosine strongly potentiates pressor responses to nicotine in rats. *Proc Natl Acad Sci U S A*. 1984;81:5599-5603.
168. Barcz E, Sommer E, Janik P et al. Adenosine receptor antagonism causes inhibition of angiogenic activity of human ovarian cancer cells. *Oncol Rep*. 2000;7:1285-1291.

169. Dulloo AG, Seydoux J, Girardier L. Potentiation of the thermogenic antiobesity effects of ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase inhibition? *Metabolism*. 1992;41:1233-1241.
170. Richter A, Hamann M. Effects of adenosine receptor agonists and antagonists in a genetic animal model of primary paroxysmal dystonia. *Br J Pharmacol*. 2001;134:343-352.
171. Satoh A, Satoh K, Masamune A et al. Activation of adenosine A2a receptor pathway reduces leukocyte infiltration but enhances edema formation in rat caerulein pancreatitis. *Pancreas*. 2002;24:75-82.
172. Dulloo AG, Seydoux J, Girardier L et al. Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity. *Int J Obes Relat Metab Disord*. 2000;24:252-258.
173. Luceri C, Caderni G, Sanna A et al. Red wine and black tea polyphenols modulate the expression of cyclooxygenase-2, inducible nitric oxide synthase and glutathione- related enzymes in azoxymethane-induced f344 rat colon tumors. *J Nutr*. 2002;132:1376-1379.
174. Richelle M, Tavazzi I, Offord E. Comparison of the antioxidant activity of commonly consumed polyphenolic beverages (coffee, cocoa, and tea) prepared per cup serving. *J Agric Food Chem*. 2001;49:3438-3442.
175. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. *J Nutr*. 2000;130:2073S-2085S.
176. Bissonnette JM, Hohimer AR, Knopp SJ. GABAergic and glutamatergic effects on behaviour in fetal sheep. *J Physiol*. 1995;487 (Pt 3):677-684.
177. Ferraro L, Antonelli T, O'Connor WT et al. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. *Neurosci Lett*. 1998;253:135-138.
178. Giovannini MG, Rakovska A, Benton RS et al. Effects of novelty and habituation on acetylcholine, GABA, and glutamate release from the frontal cortex and hippocampus of freely moving rats. *Neuroscience*. 2001;106:43-53.
179. Kiyatkin EA, Rebec GV. Modulation of striatal neuronal activity by glutamate and GABA: iontophoresis in awake, unrestrained rats. *Brain Res*. 1999;822:88-106.
180. Maloney KJ, Mainville L, Jones BE. c-Fos expression in GABAergic, serotonergic, and other neurons of the pontomedullary reticular formation and raphe after paradoxical sleep deprivation and recovery. *J Neurosci*. 2000;20:4669-4679.
181. Nitz D, Siegel JM. GABA release in posterior hypothalamus across sleep-wake cycle. *Am J Physiol*. 1996;271:R1707-R1712.
182. Nitz D, Siegel JM. GABA release in the locus coeruleus as a function of sleep/wake state. *Neuroscience*. 1997;78:795-801.
183. Nitz D, Siegel J. GABA release in the dorsal raphe nucleus: role in the control of REM sleep. *Am J Physiol*. 1997;273:R451-R455.
184. Pepeu G, Blandina P. The acetylcholine, GABA, glutamate triangle in the rat forebrain. *J Physiol Paris*. 1998;92:351-355.
185. Soltis RP, Cook JC, Gregg AE et al. Interaction of GABA and excitatory amino acids in the basolateral amygdala: role in cardiovascular regulation. *J Neurosci*. 1997;17:9367-9374.
186. Xi MC, Morales FR, Chase MH. Evidence that wakefulness and REM sleep are controlled by a GABAergic pontine mechanism. *J Neurophysiol*. 1999;82:2015-2019.
187. Adrien J, Bourgoin S, Hamon M. Midbrain raphe lesion in the newborn rat I. Neurophysiological aspects of sleep. *Brain Res*. 1977;127:99-110.

188. Barratt ES, Adams PM, Poffenbarger PL et al. Effects of rapid depletion of phenylalanine and tyrosine on sleep and behavior. *Pharmacol Biochem Behav.* 1976;5:47-53.
189. Bhatti T, Gillin JC, Seifritz E et al. Effects of a tryptophan-free amino acid drink challenge on normal human sleep electroencephalogram and mood. *Biol Psychiatry.* 1998;43:52-59.
190. Blois R, Feinberg I, Gaillard JM et al. Sleep in normal and pathological aging. *Experientia.* 1983;39:551-558.
191. Bouhuys AL, Van Den Hoofdakker RH. Effects of midbrain raphe destruction on sleep and locomotor activity in rats. *Physiol Behav.* 1977;19:535-541.
192. Bronzino JD, Morgane PJ, Stern WC. EEG synchronization following application of serotonin to area postrema. *Am J Physiol.* 1972;223:376-383.
193. Brus R, Herman ZS, Jamrozik Z et al. Action of biogenic amines injected intracerebrally on duration of hexobarbital-induced sleep in rats. *Arch Immunol Ther Exp (Warsz).* 1975;23:459-463.
194. Bryson G. Biogenic amines in normal and abnormal behavioral states. *Clin Chem.* 1971;17:5-26.
195. Cape EG, Jones BE. Differential modulation of high-frequency gamma-electroencephalogram activity and sleep-wake state by noradrenaline and serotonin microinjections into the region of cholinergic basal ganglia neurons. *J Neurosci.* 1998;18:2653-2666.
196. Carchedi F, Di Ceglie M, Casacchia M et al. [Sleep: biochemical correlations and pharmacological considerations]. *Clin Ter.* 1979;91:3-10.
197. Carlsson A. Interaction between dopaminergic and serotonergic systems. *Clin Neuropharmacol.* 1992;15 Suppl 1 Pt A:616A-617A.
198. Cespuglio R, Burette S, Faradji-Prevautel H. 5-Hydroxyindoles compounds and nitric oxide voltammetric detection in the rat brain: changes occurring throughout the sleep-wake cycle. *J Neural Transm.* 1998;105:205-215.
199. Chuman MA. The neurological basis of sleep. *Heart Lung.* 1983;12:177-182.
200. Curzon G. The role and control of brain 5-hydroxytryptamine. *Acta Neurol (Napoli).* 1977;32:121-131.
201. Drucker-Colin RR, Rojas-Ramirez JA. New approaches to the study of the neurochemical basis of sleep and wakefulness. *Adv Psychobiol.* 1976;3:1-34.
202. Dugovic C, Leysen JE, Wauquier A. Melatonin modulates the sensitivity of 5-hydroxytryptamine-2 receptor-mediated sleep-wakefulness regulation in the rat. *Neurosci Lett.* 1989;104:320-325.
203. Fornal C, Radulovacki M. Sleep suppressant action of fenfluramine in rats. I. Relation to postsynaptic serotonergic stimulation. *J Pharmacol Exp Ther.* 1983;225:667-674.
204. Fornal C, Radulovacki M. Sleep suppressant action of fenfluramine in rats. II. Evidence against the involvement of presynaptic serotonergic mechanism. *J Pharmacol Exp Ther.* 1983;225:675-681.
205. Gallopin T, Fort P, Eggermann E et al. Identification of sleep-promoting neurons in vitro. *Nature.* 2000;404:992-995.
206. Graves L, Pack A, Abel T. Sleep and memory: a molecular perspective. *Trends Neurosci.* 2001;24:237-243.
207. Grazia dS, Imeri L, De Matteo W et al. Sleep regulation: interactions among cytokines and classical neurotransmitters. *Adv Neuroimmunol.* 1995;5:189-200.
208. Guha M, Biswas S, Poddar MK. Possible involvement of central cholinergic-serotonergic interaction in natural sleep. *Methods Find Exp Clin Pharmacol.* 1988;10:243-245.
209. Hartmann E. L-tryptophan: a rational hypnotic with clinical potential. *Am J Psychiatry.* 1977;134:366-370.

210. Hill SY, Reyes RB. Effects of L-tryptophan and ethanol on sleep parameters in the rat. *Psychopharmacology (Berl)*. 1978;58:229-233.
211. Hirsh K. Central nervous system pharmacology of the dietary methylxanthines. *Prog Clin Biol Res*. 1984;158:235-301.
212. Holman RB, Elliott GR, Barchas JD. Neuroregulators and sleep mechanisms. *Annu Rev Med*. 1975;26:499-520.
213. Horner RL. Is there a rationale in modulating brainstem neurons in obstructive sleep apnea and is it clinically relevant? *Sleep*. 2000;23 Suppl 4:S179-S181.
214. Ingram DK, London ED, Reynolds MA. Circadian rhythmicity and sleep: effects of aging in laboratory animals. *Neurobiol Aging*. 1982;3:287-297.
215. Iwakiri H, Matsuyama K, Mori S. Extracellular levels of serotonin in the medial pontine reticular formation in relation to sleep-wake cycle in cats: a microdialysis study. *Neurosci Res*. 1993;18:157-170.
216. Jouvet M. [Neuromediators and hypnogenic factors]. *Rev Neurol (Paris)*. 1984;140:389-400.
217. Jouvet M. Sleep and serotonin: an unfinished story. *Neuropsychopharmacology*. 1999;21:24S-27S.
218. Koella WP. The organization and regulation of sleep. A review of the experimental evidence and a novel integrated model of the organizing and regulating apparatus. *Experientia*. 1984;40:309-338.
219. Koyama Y, Kayama Y, Sakai K. [Neural mechanisms for sleep regulation]. *Nippon Rinsho*. 1998;56:318-326.
220. Leathwood PD. Tryptophan availability and serotonin synthesis. *Proc Nutr Soc*. 1987;46:143-156.
221. Lydic R, McCarley RW, Hobson JA. Serotonin neurons and sleep. II. Time course of dorsal raphe discharge, PGO waves, and behavioral states. *Arch Ital Biol*. 1987;126:1-28.
222. Marks GA, Roffwarg HP. The cholinergic influence upon rat dorsal lateral geniculate nucleus is dependent on state of arousal. *Brain Res*. 1989;494:294-306.
223. Masek K, Kadlec O. Sleep factor, muramyl peptides, and the serotonergic system. *Lancet*. 1983;1:1277.
224. Moja EA, Mendelson WB, Stoff DM et al. Reduction of REM sleep by a tryptophan-free amino acid diet. *Life Sci*. 1979;24:1467-1470.
225. Monnier M, Gaillard JM. Biochemical regulation of sleep. *Experientia*. 1980;36:21-24.
226. Nicholson AN, Pascoe PA. 5-Hydroxytryptamine and noradrenaline uptake inhibition: studies on sleep in man. *Neuropharmacology*. 1986;25:1079-1083.
227. Pecknold JC, Luthe L. Sleep studies and neurochemical correlates in panic disorder and agoraphobia. *Prog Neuropsychopharmacol Biol Psychiatry*. 1990;14:753-758.
228. Pradhan SN, Dutta SN. Central cholinergic mechanism and behavior. *Int Rev Neurobiol*. 1971;14:173-231.
229. Puizillout JJ, Gaudin-Chazal G, Sayadi A et al. Serotonergic mechanisms and sleep. *J Physiol (Paris)*. 1981;77:415-424.
230. Sallanon M, Janin M, Buda C et al. Serotonergic mechanisms and sleep rebound. *Brain Res*. 1983;268:95-104.
231. Schulz H. [Sleep and wake-cycle as circadian rhythm (author's transl)]. *Wien Klin Wochenschr Suppl*. 1979;106:3-5.

232. Seifritz E. Contribution of sleep physiology to depressive pathophysiology. *Neuropsychopharmacology*. 2001;25:S85-S88.
233. Toru M. Proceedings: Brain monoamine metabolism and sleep. *Electroencephalogr Clin Neurophysiol*. 1975;39:542.
234. Touret M, Sarda N, Gharib A et al. The role of 5-hydroxytryptophan (5-HTP) in the regulation of the sleep/wake cycle in parachlorophenylalanine (p-CPA) pretreated rat: a multiple approach study. *Exp Brain Res*. 1991;86:117-124.
235. Turek FW, Dugovic C, Zee PC. Current understanding of the circadian clock and the clinical implications for neurological disorders. *Arch Neurol*. 2001;58:1781-1787.
236. Valatx JL. [Sleep: current data in 1990]. *Presse Med*. 1990;19:1827-1831.
237. Vasilescu E. Sleep induced by intraventricular administration of serotonin and melatonin in tortoise (*Emys orbicularis*). *Neurol Psychiatr (Bucur)*. 1982;20:125-129.
238. Wojcik WJ, Fornal C, Radulovacki M. Effect of tryptophan on sleep in the rat. *Neuropharmacology*. 1980;19:163-167.
239. Wyatt RJ, Chase TN, Kupfer DJ et al. Brain catecholamines and human sleep. *Nature*. 1971;233:63-65.
240. Yogman MW, Zeisel SH. Diet and sleep patterns in newborn infants. *N Engl J Med*. 1983;309:1147-1149.
241. Yogman MW, Zeisel SH. Nutrients, neurotransmitters and infant behavior. *Am J Clin Nutr*. 1985;42:352-360.
242. Allen RP, McCann UD, Ricaurte GA. Persistent effects of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on human sleep. *Sleep*. 1993;16:560-564.
243. Arito H, Tsuruta H, Nakagaki K et al. Partial insomnia, hyperactivity and hyperdipsia induced by repeated administration of toluene in rats: their relation to brain monoamine metabolism. *Toxicology*. 1985;37:99-110.
244. Bell C, Wilson S, Nutt DJ. Pindolol augmentation of sertraline in resistant depression and its effect on sleep. *J Psychopharmacol*. 1998;12:105-107.
245. Bhatti T, Gillin JC, Seifritz E et al. Effects of a tryptophan-free amino acid drink challenge on normal human sleep electroencephalogram and mood. *Biol Psychiatry*. 1998;43:52-59.
246. Billiard M, Besset A, Renaud B et al. [Insomnia in bismuth encephalopathy (author's transl)]. *Rev Electroencephalogr Neurophysiol Clin*. 1977;7:147-152.
247. Birmaher B, Heydl P. Biological studies in depressed children and adolescents. *Int J Neuropsychopharmacol*. 2001;4:149-157.
248. Bjorvatn B, Ursin R. Effects of zimeldine, a selective 5-HT reuptake inhibitor, combined with ritanserin, a selective 5-HT₂ antagonist, on waking and sleep stages in rats. *Behav Brain Res*. 1990;40:239-246.
249. Blois R, Feinberg I, Gaillard JM et al. Sleep in normal and pathological aging. *Experientia*. 1983;39:551-558.
250. Borbely AA, Neuhaus HU, Tobler I. Effect of p-chlorophenylalanine and tryptophan on sleep, EEG and motor activity in the rat. *Behav Brain Res*. 1981;2:1-22.
251. Brentegani LG, Brentegani MR, Lico MC. Dental pain and sleep. Experimental study on guinea pigs (*Cavia porcellus*). *Braz Dent J*. 1992;2:129-133.
252. Bronzino JD. Quantitative analysis of the EEG--general concepts and animal studies. *IEEE Trans Biomed Eng*. 1984;31:850-856.

253. Brooks DC, Gershon MD. Amine repletion in the reserpinized cat: effect upon PGO waves and REM sleep. *Electroencephalogr Clin Neurophysiol.* 1977;42:35-47.
254. Buckton G, Zibrowski EM, Vanderwolf CH. Effects of cyclazocine and scopolamine on swim-to-platform performance in rats. *Brain Res.* 2001;922:229-233.
255. Cape EG, Jones BE. Differential modulation of high-frequency gamma-electroencephalogram activity and sleep-wake state by noradrenaline and serotonin microinjections into the region of cholinergic basal ganglia neurons. *J Neurosci.* 1998;18:2653-2666.
256. Chuman MA. The neurological basis of sleep. *Heart Lung.* 1983;12:177-182.
257. Clancy JJ, Caldwell DF, Oberleas D et al. Effect of a chronic tryptophan dietary deficiency on the rat's sleep-wake cycle. *Brain Res Bull.* 1978;3:83-87.
258. Deguchi T, Sinha AK, Dement WC et al. Enzyme activity in sleep and sleep deprivation. *Pharmacol Biochem Behav.* 1975;3:957-960.
259. Erlich SS, Apuzzo ML. The pineal gland: anatomy, physiology, and clinical significance. *J Neurosurg.* 1985;63:321-341.
260. Fornal C, Wojcik WJ, Radulovacki M et al. Hypnotic effect of tryptophan analog in rats. *Pharmacol Biochem Behav.* 1979;11:319-323.
261. Fornal C, Radulovacki M. Sleep suppressant action of fenfluramine in rats. II. Evidence against the involvement of presynaptic serotonergic mechanism. *J Pharmacol Exp Ther.* 1983;225:675-681.
262. Gershon MD, Brooks DC. Monoamine oxidase inhibition and the induction of ponto-geniculate-occipital wave activity by reserpine in the cat. *J Pharmacol Exp Ther.* 1976;197:556-566.
263. Gervasoni D, Peyron C, Rampon C et al. Role and origin of the GABAergic innervation of dorsal raphe serotonergic neurons. *J Neurosci.* 2000;20:4217-4225.
264. Gromov LA, Pishel' VI. [The serotonergic mechanism and the experimental therapy of sleep disorders in desynchronization]. *Patol Fiziol Eksp Ter.* 1990;22-23.
265. Guilleminault C, Baker TL. Sleep and electroencephalography: points of interest and points of controversy. *J Clin Neurophysiol.* 1984;1:275-291.
266. Gupta MA. Is chronic pain a variant of depressive illness? A critical review. *Can J Psychiatry.* 1986;31:241-248.
267. Guzman-Marin R, Alam MN, Mihaiescu S et al. Subcutaneous administration of nicotine changes dorsal raphe serotonergic neurons discharge rate during REM sleep. *Brain Res.* 2001;888:321-325.
268. Haranath PS, Venkatakrishna-Bhatt H. Sleep induced by drugs injected into the inferior horn of the lateral cerebral ventricle in dogs. *Br J Pharmacol.* 1977;59:231-236.
269. Haranath PS, Indira G, Krishnamurthy A. Effects of cholinomimetic drugs and their antagonists injected into vertebral artery of unanaesthetized dogs. *Pharmacol Biochem Behav.* 1977;6:259-263.
270. Herdman JR, Cowen PJ, Campling GM et al. Effect of lofepramine on 5-HT function and sleep. *J Affect Disord.* 1993;29:63-72.
271. Hilaire-Kafi S, Gaillard JM. Hypnotic action of flunitrazepam in the rat: does 5-HT mechanism play a role? *Neuropharmacology.* 1988;27:1227-1230.
272. Hobson JA. Sleep and dreaming: induction and mediation of REM sleep by cholinergic mechanisms. *Curr Opin Neurobiol.* 1992;2:759-763.

273. Imeri L, De Simoni MG, Giglio R et al. Changes in the serotonergic system during the sleep-wake cycle: simultaneous polygraphic and voltammetric recordings in hypothalamus using a telemetry system. *Neuroscience*. 1994;58:353-358.
274. Imeri L, Bianchi S, Mancina M. Muramyl dipeptide and IL-1 effects on sleep and brain temperature after inhibition of serotonin synthesis. *Am J Physiol*. 1997;273:R1663-R1668.
275. Imeri L, Gemma C, De Simoni MG et al. Hypothalamic serotonergic activity correlates better with brain temperature than with sleep-wake cycle and muscle tone in rats. *Neuroscience*. 1999;89:1241-1246.
276. Imeri L, Mancina M, Bianchi S et al. 5-Hydroxytryptophan, but not L-tryptophan, alters sleep and brain temperature in rats. *Neuroscience*. 2000;95:445-452.
277. Iwakiri H, Matsuyama K, Mori S. Extracellular levels of serotonin in the medial pontine reticular formation in relation to sleep-wake cycle in cats: a microdialysis study. *Neurosci Res*. 1993;18:157-170.
278. Jaramillo J. Pharmacological studies on tandamine hydrochloride, a potential heterocyclic antidepressant. *Naunyn Schmiedebergs Arch Pharmacol*. 1978;302:107-113.
279. Kiiianmaa K, Fuxe K. The effects of 5,7-dihydroxytryptamine-induced lesions of the ascending 5-hydroxytryptamine pathways on the sleep wakefulness cycle. *Brain Res*. 1977;131:287-301.
280. Kilduff TS, Krilowicz B, Milsom WK et al. Sleep and mammalian hibernation: homologous adaptations and homologous processes? *Sleep*. 1993;16:372-386.
281. Kleinlogel H, Burki HR. Effects of the selective 5-hydroxytryptamine uptake inhibitors paroxetine and zimeldine on EEG sleep and waking stages in the rat. *Neuropsychobiology*. 1987;17:206-212.
282. Kodama T, Honda Y, Nakao M et al. Relative power contributions of unit discharges simultaneously recorded in the mesencephalic reticular formation. *Psychiatry Clin Neurosci*. 2000;54:265-267.
283. Koella WP. The organization and regulation of sleep. A review of the experimental evidence and a novel integrated model of the organizing and regulating apparatus. *Experientia*. 1984;40:309-338.
284. Koella WP. [Biochemistry and pharmacology of vigilance: role of neurotransmitters within the framework of vigilance control]. *EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb*. 1984;15:180-189.
285. Koella WP. CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action. *Eur J Clin Pharmacol*. 1985;28 Suppl:55-63.
286. Kowatch RA, Schnoll SS, Knisely JS et al. Electroencephalographic sleep and mood during cocaine withdrawal. *J Addict Dis*. 1992;11:21-45.
287. Koyama Y, Jodo E, Kayama Y. Sensory responsiveness of "broad-spike" neurons in the laterodorsal tegmental nucleus, locus coeruleus and dorsal raphe of awake rats: implications for cholinergic and monoaminergic neuron-specific responses. *Neuroscience*. 1994;63:1021-1031.
288. Kubow S, Anderson GH, Blendis LM et al. 3-methylbutanal metabolism in the adult rat. *Clin Sci (Lond)*. 1981;61:451-455.
289. Receptor physiology and hormone secretion in affective illness. *Psychopharmacol Bull*. 1983;19:479-495.
290. Bovier P, Dick P. [Current status, perspectives and limitations of serotonin precursors]. *Rev Med Suisse Romande*. 1990;110:885-890.
291. Cervera S. [Differential features of SSRIs]. *Rev Med Univ Navarra*. 1997;41:245-257.
292. Curzon G. The role and control of brain 5-hydroxytryptamine. *Acta Neurol (Napoli)*. 1977;32:121-131.

293. Dauvilliers Y, Touchon J. [Sleep in fibromyalgia: review of clinical and polysomnographic data]. *Neurophysiol Clin.* 2001;31:18-33.
294. Doogan DP. Fluvoxamine as an antidepressant drug. *Neuropharmacology.* 1980;19:1215-1216.
295. Erlich SS, Apuzzo ML. The pineal gland: anatomy, physiology, and clinical significance. *J Neurosurg.* 1985;63:321-341.
296. Gilbert JC. Psychological medicine. Drugs used in psychological medicine: pharmacological basis of treatment. *Br Med J.* 1976;1:882-884.
297. Kumar AM, Berger JR, Eisdorfer C et al. Cerebrospinal fluid 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in HIV-1 infection. *Neuropsychobiology.* 2001;44:13-18.
298. Maier J. [Psychotropic drugs for the aged. Drug therapy in geriatric psychotic disorders]. *ZFA.* 1981;36:323-330.
299. Mitsunobu K. [Depression and serotonin metabolism]. *Nippon Rinsho.* 1978;36:83-89.
300. Moller SE. [Tryptophan. Peripheral regulation of central function]. *Ugeskr Laeger.* 1979;141:458-461.
301. Moore P, Landolt HP, Seifritz E et al. Clinical and physiological consequences of rapid tryptophan depletion. *Neuropsychopharmacology.* 2000;23:601-622.
302. Murphy DL, Aulakh CS, Garrick NA. How antidepressants work: cautionary conclusions based on clinical and laboratory studies of the longer-term consequences of antidepressant drug treatment. *Ciba Found Symp.* 1986;123:106-125.
303. Perry TL, Wright JM, Berry K et al. Dominantly inherited apathy, central hypoventilation, and Parkinson's syndrome: clinical, biochemical, and neuropathologic studies of 2 new cases. *Neurology.* 1990;40:1882-1887.
304. Poitou P, Boulu R. [Psychopharmacology of tryptophan (author's transl)]. *Pathol Biol (Paris).* 1977;25:565-571.
305. Post RM, Kotin J, Goodwin FK. Effects of sleep deprivation on mood and central amine metabolism in depressed patients. *Arch Gen Psychiatry.* 1976;33:627-632.
306. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. *Depress Anxiety.* 2000;12 Suppl 1:2-19.
307. Russell IJ, Vipraio GA, Morgan WW et al. Is there a metabolic basis for the fibrositis syndrome? *Am J Med.* 1986;81:50-54.
308. Silberstein SD. Comprehensive management of headache and depression. *Cephalalgia.* 1998;18 Suppl 21:50-55.
309. Villar MJ. [New concepts relating to histochemistry of the serotonergic neural systems of the raphe nucleus]. *Acta Psychiatr Psicol Am Lat.* 1994;40:293-300.
310. Whitaker-Azmitia PM. Depression to ecstasy. The Neuropharmacology of Serotonin sponsored by the New York Academy of Sciences, New York, NY, USA, July 10-13, 1989. *New Biol.* 1989;1:145-148.
311. Wilke WS, Mackenzie AH. Proposed pathogenesis of fibrositis. *Cleve Clin Q.* 1985;52:147-154.
312. Wurtman RJ, Wurtman JJ. Brain serotonin, carbohydrate-craving, obesity and depression. *Obes Res.* 1995;3 Suppl 4:477S-480S.
313. Receptor physiology and hormone secretion in affective illness. *Psychopharmacol Bull.* 1983;19:479-495.

314. Bovier P, Dick P. [Current status, perspectives and limitations of serotonin precursors]. *Rev Med Suisse Romande*. 1990;110:885-890.
315. Cervera S. [Differential features of SSRIs]. *Rev Med Univ Navarra*. 1997;41:245-257.
316. Curzon G. The role and control of brain 5-hydroxytryptamine. *Acta Neurol (Napoli)*. 1977;32:121-131.
317. Dauvilliers Y, Touchon J. [Sleep in fibromyalgia: review of clinical and polysomnographic data]. *Neurophysiol Clin*. 2001;31:18-33.
318. Doogan DP. Fluvoxamine as an antidepressant drug. *Neuropharmacology*. 1980;19:1215-1216.
319. Erlich SS, Apuzzo ML. The pineal gland: anatomy, physiology, and clinical significance. *J Neurosurg*. 1985;63:321-341.
320. Gilbert JC. Psychological medicine. Drugs used in psychological medicine: pharmacological basis of treatment. *Br Med J*. 1976;1:882-884.
321. Moller SE. [Tryptophan. Peripheral regulation of central function]. *Ugeskr Laeger*. 1979;141:458-461.
322. Moore P, Landolt HP, Seifritz E et al. Clinical and physiological consequences of rapid tryptophan depletion. *Neuropsychopharmacology*. 2000;23:601-622.
323. Perry TL, Wright JM, Berry K et al. Dominantly inherited apathy, central hypoventilation, and Parkinson's syndrome: clinical, biochemical, and neuropathologic studies of 2 new cases. *Neurology*. 1990;40:1882-1887.
324. Poitou P, Boulu R. [Psychopharmacology of tryptophan (author's transl)]. *Pathol Biol (Paris)*. 1977;25:565-571.
325. Post RM, Kotin J, Goodwin FK. Effects of sleep deprivation on mood and central amine metabolism in depressed patients. *Arch Gen Psychiatry*. 1976;33:627-632.
326. Russell IJ, Vipraio GA, Morgan WW et al. Is there a metabolic basis for the fibrositis syndrome? *Am J Med*. 1986;81:50-54.
327. Silberstein SD. Comprehensive management of headache and depression. *Cephalalgia*. 1998;18 Suppl 21:50-55.
328. Villar MJ. [New concepts relating to histochemistry of the serotonergic neural systems of the raphe nucleus]. *Acta Psiquiatr Psicol Am Lat*. 1994;40:293-300.
329. Whitaker-Azmitia PM. Depression to ecstasy. The Neuropharmacology of Serotonin sponsored by the New York Academy of Sciences, New York, NY, USA, July 10-13, 1989. *New Biol*. 1989;1:145-148.
330. Wurtman RJ, Wurtman JJ. Brain serotonin, carbohydrate-craving, obesity and depression. *Obes Res*. 1995;3 Suppl 4:477S-480S.
331. Behan M, Zabka AG, Mitchell GS. Age and gender effects on serotonin-dependent plasticity in respiratory motor control. *Respir Physiol Neurobiol*. 2002;131:65-77.
332. Carley DW, Radulovacki M. Role of peripheral serotonin in the regulation of central sleep apneas in rats. *Chest*. 1999;115:1397-1401.
333. Dauvilliers Y, Touchon J. [Sleep in fibromyalgia: review of clinical and polysomnographic data]. *Neurophysiol Clin*. 2001;31:18-33.
334. Grunstein RR, Hedner J, Grote L. Treatment options for sleep apnoea. *Drugs*. 2001;61:237-251.

335. Hilaire G, Morin D, Lajard AM et al. Changes in serotonin metabolism may elicit obstructive apnoea in the newborn rat. *J Physiol*. 1993;466:367-381.
336. Horner RL. Is there a rationale in modulating brainstem neurons in obstructive sleep apnea and is it clinically relevant? *Sleep*. 2000;23 Suppl 4:S179-S181.
337. Hudgel DW. Pharmacologic treatment of obstructive sleep apnea. *J Lab Clin Med*. 1995;126:13-18.
338. Hudgel DW, Gordon EA, Meltzer HY. Abnormal serotonergic stimulation of cortisol production in obstructive sleep apnea. *Am J Respir Crit Care Med*. 1995;152:186-192.
339. Hudgel DW, Gordon EA. Serotonin-induced cortisol release in CPAP-treated obstructive sleep apnea patients. *Chest*. 1997;111:632-638.
340. Kraiczi H, Hedner J, Dahlof P et al. Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. *Sleep*. 1999;22:61-67.
341. Morin D, Di Pasquale E, Hilaire G et al. Possible involvement of serotonin in obstructive apnea of the newborn. *Biol Neonate*. 1994;65:176-181.
342. Okabe S. [Future direction of therapies for sleep related breathing disorders]. *Nippon Rinsho*. 2000;58:1693-1697.
343. Plantamura A, Steinbauer J, Eisinger J. [Sleep apnea and fibromyalgia: the absence of correlation does not indicate an exclusive central hypothesis]. *Rev Med Interne*. 1995;16:662-665.
344. Radulovacki M, Trbovic SM, Carley DW. Serotonin 5-HT₃-receptor antagonist GR 38032F suppresses sleep apneas in rats. *Sleep*. 1998;21:131-136.
345. Saito Y, Ito M, Ozawa Y et al. Changes of neurotransmitters in the brainstem of patients with respiratory-pattern disorders during childhood. *Neuropediatrics*. 1999;30:133-140.
346. Schmidt HS. L-tryptophan in the treatment of impaired respiration in sleep. *Bull Eur Physiopathol Respir*. 1983;19:625-629.
347. Sunderram J, Parisi RA, Strobel RJ. Serotonergic stimulation of the genioglossus and the response to nasal continuous positive airway pressure. *Am J Respir Crit Care Med*. 2000;162:925-929.
348. Veasey SC, Panckeri KA, Hoffman EA et al. The effects of serotonin antagonists in an animal model of sleep-disordered breathing. *Am J Respir Crit Care Med*. 1996;153:776-786.
349. Veasey SC. Serotonin. Culprit or promising therapy for obstructive sleep apnea? *Am J Respir Crit Care Med*. 2001;163:1045-1047.
350. Veasey SC. Pharmacotherapies for obstructive sleep apnea: how close are we? *Curr Opin Pulm Med*. 2001;7:399-403.
351. Muzur A, Pace-Schott EF, Hobson JA. The prefrontal cortex in sleep. *Trends Cogn Sci*. 2002;6:475-481.
352. Sawaguchi T, Franco P, Kato I et al. From physiology to pathology: arousal deficiency theory in sudden infant death syndrome (SIDS)--with reference to apoptosis and neuronal plasticity. *Forensic Sci Int*. 2002;130 Suppl:S37-S43.
353. Cohen G, Han ZY, Grailhe R et al. beta 2 nicotinic acetylcholine receptor subunit modulates protective responses to stress: A receptor basis for sleep-disordered breathing after nicotine exposure. *Proc Natl Acad Sci U S A*. 2002;99:13272-13277.
354. Bellingham MC, Ireland MF. Contribution of cholinergic systems to state-dependent modulation of respiratory control. *Respir Physiol Neurobiol*. 2002;131:135-144.

355. Joseph V, Pequignot JM, Van Reeth O. Neurochemical perspectives on the control of breathing during sleep. *Respir Physiol Neurobiol*. 2002;130:253-263.
356. Eggermann E, Serafin M, Bayer L et al. Orexins/hypocretins excite basal forebrain cholinergic neurones. *Neuroscience*. 2001;108:177-181.
357. Seifritz E. Contribution of sleep physiology to depressive pathophysiology. *Neuropsychopharmacology*. 2001;25:S85-S88.
358. Hasselmo ME, Fehlau BP. Differences in time course of ACh and GABA modulation of excitatory synaptic potentials in slices of rat hippocampus. *J Neurophysiol*. 2001;86:1792-1802.
359. Solms M. Dreaming and REM sleep are controlled by different brain mechanisms. *Behav Brain Sci*. 2000;23:843-850.
360. Graves L, Pack A, Abel T. Sleep and memory: a molecular perspective. *Trends Neurosci*. 2001;24:237-243.
361. Krahn LE, Black JL, Silber MH. Narcolepsy: new understanding of irresistible sleep. *Mayo Clin Proc*. 2001;76:185-194.
362. Vazquez J, Baghdoyan HA. Basal forebrain acetylcholine release during REM sleep is significantly greater than during waking. *Am J Physiol Regul Integr Comp Physiol*. 2001;280:R598-R601.
363. Cudeiro J, Rivadulla C, Grieve KL. A possible role for nitric oxide at the sleep/wake interface. *Sleep*. 2000;23:829-835.
364. Kraiczi H, Hedner J, Peker Y et al. Increased vasoconstrictor sensitivity in obstructive sleep apnea. *J Appl Physiol*. 2000;89:493-498.
365. Gallopin T, Fort P, Eggermann E et al. Identification of sleep-promoting neurons in vitro. *Nature*. 2000;404:992-995.
366. Thomas AJ, Erokwu BO, Yamamoto BK et al. Alterations in respiratory behavior, brain neurochemistry and receptor density induced by pharmacologic suppression of sleep in the neonatal period. *Brain Res Dev Brain Res*. 2000;120:181-189.
367. Sarter M, Bruno JP. Cortical cholinergic inputs mediating arousal, attentional processing and dreaming: differential afferent regulation of the basal forebrain by telencephalic and brainstem afferents. *Neuroscience*. 2000;95:933-952.
368. Hasselmo ME. Neuromodulation: acetylcholine and memory consolidation. *Trends Cogn Sci*. 1999;3:351-359.
369. Manaye KF, Zweig R, Wu D et al. Quantification of cholinergic and select non-cholinergic mesopontine neuronal populations in the human brain. *Neuroscience*. 1999;89:759-770.
370. Kayama Y, Koyama Y. Brainstem neural mechanisms of sleep and wakefulness. *Eur Urol*. 1998;33 Suppl 3:12-15.
371. Koyama Y, Kayama Y, Sakai K. [Neural mechanisms for sleep regulation]. *Nippon Rinsho*. 1998;56:318-326.
372. Capece ML, Lydic R. cAMP and protein kinase A modulate cholinergic rapid eye movement sleep generation. *Am J Physiol*. 1997;273:R1430-R1440.
373. Steininger TL, Wainer BH, Blakely RD et al. Serotonergic dorsal raphe nucleus projections to the cholinergic and noncholinergic neurons of the pedunculo-pontine tegmental region: a light and electron microscopic anterograde tracing and immunohistochemical study. *J Comp Neurol*. 1997;382:302-322.
374. Carlson JT, Rangemark C, Hedner JA. Attenuated endothelium-dependent vascular relaxation in patients with sleep apnoea. *J Hypertens*. 1996;14:577-584.

375. Grazia dS, Imeri L, De Matteo W et al. Sleep regulation: interactions among cytokines and classical neurotransmitters. *Adv Neuroimmunol*. 1995;5:189-200.
376. Williams JA, Comisarow J, Day J et al. State-dependent release of acetylcholine in rat thalamus measured by in vivo microdialysis. *J Neurosci*. 1994;14:5236-5242.
377. Salin-Pascual RJ, Jimenez-Anguiano A, Duran-Vazquez A et al. Administration of auditory stimulation during recovery after REM sleep deprivation. *Sleep*. 1994;17:231-235.
378. Szymusiak R, McGinty D, Fairchild MD et al. Sleep-wake disturbances in an animal model of chronic cholinergic insufficiency. *Brain Res*. 1993;629:141-145.
379. Brown DW. Abnormal fluctuations of acetylcholine and serotonin. *Med Hypotheses*. 1993;40:309-310.
380. Gillin JC, Salin-Pascual R, Velazquez-Moctezuma J et al. Cholinergic receptor subtypes and REM sleep in animals and normal controls. *Prog Brain Res*. 1993;98:379-387.
381. Hobson JA. Sleep and dreaming: induction and mediation of REM sleep by cholinergic mechanisms. *Curr Opin Neurobiol*. 1992;2:759-763.
382. McCormick DA. Neurotransmitter actions in the thalamus and cerebral cortex. *J Clin Neurophysiol*. 1992;9:212-223.
383. Machowski R, Ansseau M, Charles G et al. Latencies of REM sleep and awakening in major depression: possible indicators of cholinergic activity. *Neurophysiol Clin*. 1989;19:385-391.
384. Marks GA, Roffwarg HP. The cholinergic influence upon rat dorsal lateral geniculate nucleus is dependent on state of arousal. *Brain Res*. 1989;494:294-306.
385. Musa MN. Sleep apnea following withdrawal of amitriptyline. *J Clin Pharmacol*. 1988;28:1038-1039.
386. Yamamoto J. Roles of cholinergic, dopaminergic, noradrenergic, serotonergic and GABAergic systems in changes of the EEG power spectra and behavioral states in rabbits. *Jpn J Pharmacol*. 1988;47:123-134.
387. Leong SS, Brown WA. Acetylcholine and affective disorder. *J Neural Transm*. 1987;70:295-312.
388. Barnes PJ. Circadian variation in airway function. *Am J Med*. 1985;79:5-9.
389. Gillin JC, Sitaram N. Rapid eye movement (REM) sleep: cholinergic mechanisms. *Psychol Med*. 1984;14:501-506.
390. Masserano JM, King C. Effects on sleep of acetylcholine perfusion of the locus coeruleus of cats. *Neuropharmacology*. 1982;21:1163-1167.
391. Sitaram N, Nurnberger JI, Jr., Gershon ES et al. Cholinergic regulation of mood and REM sleep: potential model and marker of vulnerability to affective disorder. *Am J Psychiatry*. 1982;139:571-576.
392. Gillin JC, Sitaram N, Mendelson WB. Acetylcholine, sleep, and depression. *Hum Neurobiol*. 1982;1:211-219.
393. Monnier M, Gaillard JM. Biochemical regulation of sleep. *Experientia*. 1980;36:21-24.
394. Cape EG, Jones BE. Effects of glutamate agonist versus procaine microinjections into the basal forebrain cholinergic cell area upon gamma and theta EEG activity and sleep-wake state. *Eur J Neurosci*. 2000;12:2166-2184.
395. Carchedi F, Di Ceglie M, Casacchia M et al. [Sleep: biochemical correlations and pharmacological considerations]. *Clin Ter*. 1979;91:3-10.

396. Costentin J. [Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation]. *Encephale*. 1979;5:121-149.
397. Danneberg P, Weber KH. Chemical structure and biological activity of the diazepam. *Br J Clin Pharmacol*. 1983;16 Suppl 2:231S-244S.
398. de Lecea L, Criado JR, Prospero-Garcia O et al. A cortical neuropeptide with neuronal depressant and sleep-modulating properties. *Nature*. 1996;381:242-245.
399. Drucker-Colin RR, Rojas-Ramirez JA. New approaches to the study of the neurochemical basis of sleep and wakefulness. *Adv Psychobiol*. 1976;3:1-34.
400. Gaillard JM. Neurochemical regulation of the states of alertness. *Ann Clin Res*. 1985;17:175-184.
401. Gallopin T, Fort P, Eggermann E et al. Identification of sleep-promoting neurons in vitro. *Nature*. 2000;404:992-995.
402. Gerashchenko D, Salin-Pascual R, Shiromani PJ. Effects of hypocretin-saporin injections into the medial septum on sleep and hippocampal theta. *Brain Res*. 2001;913:106-115.
403. Horton RC, Logan SD, Wolstencroft JH. A microiontophoretic study of the actions of the putative sleep factor, piperidine, in the rat brainstem. *Br J Pharmacol*. 1985;85:37-44.
404. Kameyama T, Nabeshima T, Noda Y. [Behavioral pharmacological action of Ca-4-(3,5-dihydroxy-3-methylpentylamido) butyrate (mevalonic GABA, MV-GABA)]. *Nippon Yakurigaku Zasshi*. 1987;89:103-110.
405. Koella WP. The organization and regulation of sleep. A review of the experimental evidence and a novel integrated model of the organizing and regulating apparatus. *Experientia*. 1984;40:309-338.
406. Marks GA, Roffwarg HP. The cholinergic influence upon rat dorsal lateral geniculate nucleus is dependent on state of arousal. *Brain Res*. 1989;494:294-306.
407. Oliverio A, Castellano C, Puglisi-Allegra S. Psychobiology of opioids. *Int Rev Neurobiol*. 1984;25:277-337.
408. Szymusiak R. Magnocellular nuclei of the basal forebrain: substrates of sleep and arousal regulation. *Sleep*. 1995;18:478-500.
409. Tartara A, Maurelli M, Marchioni E. Electroencephalographic and autonomic effects of centrally administered dermorphin in rabbits. *Peptides*. 1985;6 Suppl 3:143-147.
410. Cape EG, Jones BE. Effects of glutamate agonist versus procaine microinjections into the basal forebrain cholinergic cell area upon gamma and theta EEG activity and sleep-wake state. *Eur J Neurosci*. 2000;12:2166-2184.
411. Carchedi F, Di Ceglie M, Casacchia M et al. [Sleep: biochemical correlations and pharmacological considerations]. *Clin Ter*. 1979;91:3-10.
412. de Lecea L, Criado JR, Prospero-Garcia O et al. A cortical neuropeptide with neuronal depressant and sleep-modulating properties. *Nature*. 1996;381:242-245.
413. Gallopin T, Fort P, Eggermann E et al. Identification of sleep-promoting neurons in vitro. *Nature*. 2000;404:992-995.
414. Gerashchenko D, Salin-Pascual R, Shiromani PJ. Effects of hypocretin-saporin injections into the medial septum on sleep and hippocampal theta. *Brain Res*. 2001;913:106-115.
415. Horton RC, Logan SD, Wolstencroft JH. A microiontophoretic study of the actions of the putative sleep factor, piperidine, in the rat brainstem. *Br J Pharmacol*. 1985;85:37-44.

416. Kameyama T, Nabeshima T, Noda Y. [Behavioral pharmacological action of Ca-4-(3,5-dihydroxy-3-methylpentylamido) butyrate (mevalonic GABA, MV-GABA)]. *Nippon Yakurigaku Zasshi*. 1987;89:103-110.
417. Koella WP. The organization and regulation of sleep. A review of the experimental evidence and a novel integrated model of the organizing and regulating apparatus. *Experientia*. 1984;40:309-338.
418. Marks GA, Roffwarg HP. The cholinergic influence upon rat dorsal lateral geniculate nucleus is dependent on state of arousal. *Brain Res*. 1989;494:294-306.
419. Szymusiak R. Magnocellular nuclei of the basal forebrain: substrates of sleep and arousal regulation. *Sleep*. 1995;18:478-500.
420. Agarwal KN. Iron and the brain: neurotransmitter receptors and magnetic resonance spectroscopy. *Br J Nutr*. 2001;85 Suppl 2:S147-S150.
421. Binns KE. The synaptic pharmacology underlying sensory processing in the superior colliculus. *Prog Neurobiol*. 1999;59:129-159.
422. Fabian-Fine R, Skehel P, Errington ML et al. Ultrastructural distribution of the alpha7 nicotinic acetylcholine receptor subunit in rat hippocampus. *J Neurosci*. 2001;21:7993-8003.
423. Galluzzi S, Zanetti O, Binetti G et al. Coma in a patient with Alzheimer's disease taking low dose trazodone and ginkgo biloba. *J Neurol Neurosurg Psychiatry*. 2000;68:679-680.
424. Giuliano F, Rampin O, Allard J. Neurophysiology and pharmacology of female genital sexual response. *J Sex Marital Ther*. 2002;28 Suppl 1:101-121.
425. Haxhiu MA, Mack SO, Martin RJ et al. Behavioral state control and airway instability. *Adv Exp Med Biol*. 2001;499:445-450.
426. Johnston GA. Medicinal chemistry and molecular pharmacology of GABA(C) receptors. *Curr Top Med Chem*. 2002;2:903-913.
427. Johnston GA. Medicinal chemistry and molecular pharmacology of GABA(C) receptors. *Curr Top Med Chem*. 2002;2:903-913.
428. Kimura T, Ho IK, Yamamoto I. Uridine receptor: discovery and its involvement in sleep mechanism. *Sleep*. 2001;24:251-260.
429. Lemoine P, Allain H. Induction of sleep. *Sleep*. 1996;19:S1-S6.
430. Liao JF, Huang SY, Jan YM et al. Central inhibitory effects of water extract of *Acori graminei* rhizoma in mice. *J Ethnopharmacol*. 1998;61:185-193.
431. Nutt DJ. Neurobiological mechanisms in generalized anxiety disorder. *J Clin Psychiatry*. 2001;62 Suppl 11:22-27.
432. Vazquez-Palacios G, Bonilla-Jaime H, Retana-Marquez S et al. Copulatory activity increases slow-wave sleep in the male rat. *J Sleep Res*. 2002;11:237-245.
433. Choi S, Jonak EM, Simpson L et al. Intermittent, chronic fenfluramine administration to rats repeatedly suppresses food intake despite substantial brain serotonin reductions. *Brain Res*. 2002;928:30-39.
434. Colmenares JL, Wurtman RJ, Fernstrom JD. Effects of ingestion of a carbohydrate-fat meal on the levels and synthesis of 5-hydroxyindoles in various regions of the rat central nervous system. *J Neurochem*. 1975;25:825-829.
435. Fernstrom JD, Wurtman RJ. Brain serotonin content: increase following ingestion of carbohydrate diet. *Science*. 1971;174:1023-1025.

436. Fernstrom JD, Wurtman RJ. Brain serotonin content: physiological regulation by plasma neutral amino acids. *Science*. 1972;178:414-416.
437. Fernstrom JD. Dietary precursors and brain neurotransmitter formation. *Annu Rev Med*. 1981;32:413-425.
438. Fernstrom JD. Effects of the diet on brain function. *Acta Astronaut*. 1981;8:1035-1042.
439. Fernstrom JD, Fernstrom MH. Monoamines and protein intake: are control mechanisms designed to monitor a threshold intake or a set point? *Nutr Rev*. 2001;59:S60-S65.
440. Fernstrom JD, Fernstrom MH. Diet, monoamine neurotransmitters and appetite control. *Nestle Nutr Workshop Ser Clin Perform Programme*. 2001;117-131.
441. Fernstrom JD. Can nutrient supplements modify brain function? *Am J Clin Nutr*. 2000;71:1669S-1675S.
442. Fernstrom JD, Wurtman RJ. Brain serotonin content: physiological regulation by plasma neutral amino acids. 1971. *Obes Res*. 1997;5:377-380.
443. Fernstrom JD. Dietary amino acids and brain function. *J Am Diet Assoc*. 1994;94:71-77.
444. Fernstrom JD. Tryptophan, serotonin and carbohydrate appetite: will the real carbohydrate craver please stand up! *J Nutr*. 1988;118:1417-1419.
445. Fernstrom JD. Food-induced changes in brain serotonin synthesis: is there a relationship to appetite for specific macronutrients? *Appetite*. 1987;8:163-182.
446. Fernstrom JD. Dietary effects on brain serotonin synthesis: relationship to appetite regulation. *Am J Clin Nutr*. 1985;42:1072-1082.
447. Fernstrom JD. Acute effects of tryptophan and single meals on serotonin synthesis in the rat brain. *Adv Biochem Psychopharmacol*. 1982;34:85-106.
448. Fernstrom JD. Dietary precursors and brain neurotransmitter formation. *Annu Rev Med*. 1981;32:413-425.
449. Fernstrom JD, Wurtman RJ, Hammarstrom-Wiklund B et al. Diurnal variations in plasma neutral amino acid concentrations among patients with cirrhosis: effect of dietary protein. *Am J Clin Nutr*. 1979;32:1923-1933.
450. Fernstrom JD, Faller DV. Neutral amino acids in the brain: changes in response to food ingestion. *J Neurochem*. 1978;30:1531-1538.
451. Fernstrom JD, Hirsch MJ. Brain serotonin synthesis: reduction in corn-malnourished rats. *J Neurochem*. 1977;28:877-879.
452. Fernstrom JD. Effects on the diet on brain neurotransmitters. *Metabolism*. 1977;26:207-223.
453. Fernstrom JD, Munro HN, Wurtman RJ. Brain tryptophan in rats on a high fat diet. *Nature*. 1977;265:277.
454. Fernstrom JD, Hirsch MJ, Faller DV. Tryptophan concentrations in rat brain. Failure to correlate with free serum tryptophan or its ratio to the sum of other serum neutral amino acids. *Biochem J*. 1976;160:589-595.
455. Fernstrom JD, Lytle LD. Corn malnutrition, brain serotonin and behavior. *Nutr Rev*. 1976;34:257-262.
456. Fernstrom JD, Hirsch NJ. Rapid repletion of brain serotonin in malnourished corn-fed rats following L-tryptophan injection. *Life Sci*. 1975;17:455-463.
457. Fernstrom JD, Wurtman RJ. Nutrition and the brain. *Sci Am*. 1974;230:84-91.
458. Fernstrom JD, Wurtman RJ. Control of brain serotonin levels by the diet. *Adv Biochem Psychopharmacol*. 1974;11:133-142.

459. Fernstrom JD, Wurtman RJ. Effect of chronic corn consumption on serotonin content of rat brain. *Nat New Biol.* 1971;234:62-64.
460. Fernstrom JD. Effects of the diet and other metabolic phenomena on brain tryptophan uptake and serotonin synthesis. *Adv Exp Med Biol.* 1991;294:369-376.
461. Fernstrom JD. Tryptophan, serotonin and carbohydrate appetite: will the real carbohydrate craver please stand up! *J Nutr.* 1988;118:1417-1419.
462. Fernstrom JD, Wurtman RJ. Nutrition and the brain. *Sci Am.* 1974;230:84-91.
463. Lehnert H, Wurtman RJ. Amino acid control of neurotransmitter synthesis and release: physiological and clinical implications. *Psychother Psychosom.* 1993;60:18-32.
464. Ross DS, Fernstrom JD, Wurtman RJ. The role of dietary protein in generating daily rhythms in rat liver tryptophan pyrrolase and tyrosine transaminase. *Metabolism.* 1973;22:1175-1184.
465. Spedding M, Ouvry C, Millan M et al. Neural control of dieting. *Nature.* 1996;380:488.
466. Wurtman J. Control of carbohydrate intake in young and adult animals. *Int J Obes.* 1980;4:310-313.
467. Wurtman JJ, Wurtman RJ. Drugs that enhance central serotonergic transmission diminish elective carbohydrate consumption by rats. *Life Sci.* 1979;24:895-903.
468. Wurtman JJ. The involvement of brain serotonin in excessive carbohydrate snacking by obese carbohydrate cravers. *J Am Diet Assoc.* 1984;84:1004-1007.
469. Wurtman JJ. Neurotransmitter control of carbohydrate consumption. *Ann N Y Acad Sci.* 1985;443:145-151.
470. Wurtman JJ. Disorders of food intake. Excessive carbohydrate snack intake among a class of obese people. *Ann N Y Acad Sci.* 1987;499:197-202.
471. Wurtman JJ. Depression and weight gain: the serotonin connection. *J Affect Disord.* 1993;29:183-192.
472. Wurtman JJ. Carbohydrate craving, mood changes, and obesity. *J Clin Psychiatry.* 1988;49 Suppl:37-39.
473. Wurtman JJ. Carbohydrate craving. Relationship between carbohydrate intake and disorders of mood. *Drugs.* 1990;39 Suppl 3:49-52.
474. Wurtman JJ, Wurtman RJ. Studies on the appetite for carbohydrates in rats and humans. *J Psychiatr Res.* 1982;17:213-221.
475. Wurtman JJ. Carbohydrate cravings: a disorder of food intake and mood. *Clin Neuropharmacol.* 1988;11 Suppl 1:S139-S145.
476. Wurtman JJ, Fernstrom JD. Free amino acid, protein, and fat contents of breast milk from Guatemalan mothers consuming a corn-based diet. *Early Hum Dev.* 1979;3:67-77.
477. Wurtman JJ, Moses PL, Wurtman RJ. Prior carbohydrate consumption affects the amount of carbohydrate that rats choose to eat. *J Nutr.* 1983;113:70-78.
478. Wurtman JJ, Wurtman RJ. Studies on the appetite for carbohydrates in rats and humans. *J Psychiatr Res.* 1982;17:213-221.
479. Wurtman RJ, Fernstrom JD. Control of brain serotonin by the diet. *Adv Neurol.* 1974;5:19-29.
480. Wurtman RJ, Fernstrom JD. Control of brain monoamine synthesis by diet and plasma amino acids. *Am J Clin Nutr.* 1975;28:638-647.
481. Wurtman RJ. Dietary treatments that affect brain neurotransmitters. Effects on calorie and nutrient intake. *Ann N Y Acad Sci.* 1987;499:179-190.

482. Wurtman RJ, Wurtman JJ. Do carbohydrates affect food intake via neurotransmitter activity? *Appetite*. 1988;11 Suppl 1:42-47.
483. Wurtman RJ. Neurotransmitters, control of appetite, and obesity. *Curr Concepts Nutr*. 1988;16:27-34.
484. Wurtman RJ, Wurtman JJ. Brain serotonin, carbohydrate-craving, obesity and depression. *Obes Res*. 1995;3 Suppl 4:477S-480S.
485. Wurtman RJ. Nutrients affecting brain composition and behavior. *Integr Psychiatry*. 1987;5:226-238.
486. Wurtman RJ, Wurtman JJ. Carbohydrate craving, obesity and brain serotonin. *Appetite*. 1986;7 Suppl:99-103.
487. Wurtman RJ, Fernstrom JD. Control of brain monoamine synthesis by diet and plasma amino acids. *Am J Clin Nutr*. 1975;28:638-647.
488. Wurtman RJ, Fernstrom JD. Control of brain serotonin by the diet. *Adv Neurol*. 1974;5:19-29.
489. Wurtman RJ. Behavioural effects of nutrients. *Lancet*. 1983;1:1145-1147.
490. Aberg-Wistedt A, Hasselmark L, Stain-Malmgren R et al. Serotonergic 'vulnerability' in affective disorder: a study of the tryptophan depletion test and relationships between peripheral and central serotonin indexes in citalopram-responders. *Acta Psychiatr Scand*. 1998;97:374-380.
491. Abou-Saleh MT, Coppen A. The biology of folate in depression: implications for nutritional hypotheses of the psychoses. *J Psychiatr Res*. 1986;20:91-101.
492. Adams WR, Kiefer SW, Badia-Elder N. Tryptophan deficiency and alcohol consumption in rats as a model for disadvantaged human populations: a preliminary study. *Med Anthropol*. 1995;16:175-191.
493. Ahveninen J, Kahkonen S, Pennanen S et al. Tryptophan depletion effects on EEG and MEG responses suggest serotonergic modulation of auditory involuntary attention in humans. *Neuroimage*. 2002;16:1052-1061.
494. Ahveninen J, Jaaskelainen IP, Pennanen S et al. Auditory selective attention modulated by tryptophan depletion in humans. *Neurosci Lett*. 2003;340:181-184.
495. Akarte NR, Shastri NV. Studies on tryptophan-niacin metabolism in streptozotocin diabetic rats. *Diabetes*. 1974;23:977-981.
496. Anderson GH, Johnston JL. Nutrient control of brain neurotransmitter synthesis and function. *Can J Physiol Pharmacol*. 1983;61:271-281.
497. Anderson IM, Mortimore C. 5-HT and human anxiety. Evidence from studies using acute tryptophan depletion. *Adv Exp Med Biol*. 1999;467:43-55.
498. Anderson IM, Richell RA, Bradshaw CM. The effect of acute tryptophan depletion on probabilistic choice. *J Psychopharmacol*. 2003;17:3-7.
499. Angel-Meza AR, Gonzalez-Burgos I, Olvera-Cortes E et al. Chronic tryptophan restriction disrupts grooming chain completion in the rat. *Physiol Behav*. 1996;59:1099-1102.
500. Angel-Meza AR, Ramirez-Cortes L, Olvera-Cortes E et al. A tryptophan-deficient corn-based diet induces plastic responses in cerebellar cortex cells of rat offspring. *Int J Dev Neurosci*. 2001;19:447-453.
501. Angel-Meza AR, Ramirez-Cortes L, Adame-Gonzalez IG et al. Cerebral GABA release and GAD activity in protein- and tryptophan-restricted rats during development. *Int J Dev Neurosci*. 2002;20:47-54.
502. Anthony TG, Reiter AK, Anthony JC et al. Deficiency of dietary EAA preferentially inhibits mRNA translation of ribosomal proteins in liver of meal-fed rats. *Am J Physiol Endocrinol Metab*. 2001;281:E430-E439.

503. Aoyagi K, Oomura Y, Shimizu N. Concurrent measurement of serotonin metabolism and single neuron activity changes in the lateral hypothalamus of freely behaving rat. *Behav Brain Res.* 1992;49:205-212.
504. Aquilio E, Seri S. Effects of dietary changes on muricide activity in adult and young rats. *Boll Soc Ital Biol Sper.* 1983;59:717-722.
505. Arnulf I, Quintin P, Alvarez JC et al. Mid-morning tryptophan depletion delays REM sleep onset in healthy subjects. *Neuropsychopharmacology.* 2002;27:843-851.
506. Arrendondo-Vega FX, Santisteban I, Notarangelo LD et al. Seven novel mutations in the adenosine deaminase (ADA) gene in patients with severe and delayed onset combined immunodeficiency: G74C, V129M, G140E, R149W, Q199P, 462delG, and E337del. Mutations in brief no. 142. Online. *Hum Mutat.* 1998;11:482.
507. Bach A. Oxaloacetate deficiency in MCT-induced ketogenesis. *Arch Int Physiol Biochim.* 1978;86:1133-1142.
508. Badawy AA, Morgan CJ, Thomas R. Tryptophan and 5-hydroxytryptamine metabolism in alcoholism. *Alcohol Alcohol Suppl.* 1993;2:231-235.
509. Badawy AA. Tryptophan metabolism in alcoholism. *Adv Exp Med Biol.* 1999;467:265-274.
510. Barbui C, Garattini S. Tryptophan and depression. *Lancet.* 1997;349:1553-1554.
511. Bel N, Artigas F. Reduction of serotonergic function in rat brain by tryptophan depletion: effects in control and fluvoxamine-treated rats. *J Neurochem.* 1996;67:669-676.
512. Bell C, Abrams J, Nutt D. Tryptophan depletion and its implications for psychiatry. *Br J Psychiatry.* 2001;178:399-405.
513. Bender DA. Tryptophan and niacin nutrition--is there a problem? *Adv Exp Med Biol.* 1996;398:565-569.
514. Benkelfat C, Ellenbogen MA, Dean P et al. Mood-lowering effect of tryptophan depletion. Enhanced susceptibility in young men at genetic risk for major affective disorders. *Arch Gen Psychiatry.* 1994;51:687-697.
515. Benkelfat C, Seletti B, Palmour RM et al. Tryptophan depletion in stable lithium-treated patients with bipolar disorder in remission. *Arch Gen Psychiatry.* 1995;52:154-156.
516. Benton D, Donohoe RT. The effects of nutrients on mood. *Public Health Nutr.* 1999;2:403-409.
517. Bjork JM, Dougherty DM, Moeller FG et al. The effects of tryptophan depletion and loading on laboratory aggression in men: time course and a food-restricted control. *Psychopharmacology (Berl).* 1999;142:24-30.
518. Bjork JM, Dougherty DM, Moeller FG et al. Differential behavioral effects of plasma tryptophan depletion and loading in aggressive and nonaggressive men. *Neuropsychopharmacology.* 2000;22:357-369.
519. Bleiberg-Daniel F, Le Moullac B, Maire JC et al. Failure of tryptophan deficiency to reduce specifically serum levels of transthyretin or albumin in rats. *J Nutr.* 1990;120:1610-1616.
520. Booij L, Van der DW, Benkelfat C et al. Predictors of mood response to acute tryptophan depletion. A reanalysis. *Neuropsychopharmacology.* 2002;27:852-861.
521. Booth DA, French JA, Wainwright CJ et al. Personal benefits from post-ingestional actions of dietary constituents. *Proc Nutr Soc.* 1992;51:335-341.
522. Brown CM, Fletcher PJ, Coscina DV. Acute amino acid loads that deplete brain serotonin fail to alter behavior. *Pharmacol Biochem Behav.* 1998;59:115-121.

523. Burgund ED, Marsolek CJ, Luciana M. Serotonin levels influence patterns of repetition priming. *Neuropsychology*. 2003;17:161-170.
524. Byerley WF, Risch SC. Depression and serotonin metabolism: rationale for neurotransmitter precursor treatment. *J Clin Psychopharmacol*. 1985;5:191-206.
525. Calapai G, Corica F, Corsonello A et al. Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis. *J Clin Invest*. 1999;104:975-982.
526. Carew LB, Jr., Alster FA, Foss DC et al. Effect of a tryptophan deficiency on thyroid gland, growth hormone and testicular functions in chickens. *J Nutr*. 1983;113:1756-1765.
527. Carpenter LL, Anderson GM, Pelton GH et al. Tryptophan depletion during continuous CSF sampling in healthy human subjects. *Neuropsychopharmacology*. 1998;19:26-35.
528. Chang YO, Soong CC. Effect of feeding diets lacking various essential amino acids on body composition of rats. *Int J Vitam Nutr Res*. 1975;45:230-236.
529. Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. *J Clin Psychiatry*. 1998;59 Suppl 14:11-14.
530. Clancy JJ, Caldwell DF, Oberleas D et al. Effect of a chronic tryptophan dietary deficiency on the rat's sleep-wake cycle. *Brain Res Bull*. 1978;3:83-87.
531. Clark JA, Clark MS, Palfreyman ES et al. The effect of tryptophan and a tryptophan/5-hydroxytryptophan combination on indoles in the brains of rats fed a tryptophan deficient diet. *Psychopharmacologia*. 1975;45:183-188.
532. Cleare AJ, Bond AJ. Effects of alterations in plasma tryptophan levels on aggressive feelings. *Arch Gen Psychiatry*. 1994;51:1004-1005.
533. Cleare AJ, Bond AJ. Experimental evidence that the aggressive effect of tryptophan depletion is mediated via the 5-HT1A receptor. *Psychopharmacology (Berl)*. 2000;147:439-441.
534. Clemens JA, Bennett DR, Fuller RW. The effect of a tryptophan-free diet on prolactin and corticosterone release by serotonergic stimuli. *Horm Metab Res*. 1980;12:35-38.
535. Delgado PL, Charney DS, Price LH et al. Neuroendocrine and behavioral effects of dietary tryptophan restriction in healthy subjects. *Life Sci*. 1989;45:2323-2332.
536. Delgado PL, Charney DS, Price LH et al. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. *Arch Gen Psychiatry*. 1990;47:411-418.
537. Delgado PL, Price LH, Miller HL et al. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. *Arch Gen Psychiatry*. 1994;51:865-874.
538. Delgado PL, Miller HL, Salomon RM et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. *Biol Psychiatry*. 1999;46:212-220.
539. Aberg-Wistedt A, Hasselmark L, Stain-Malmgren R et al. Serotonergic 'vulnerability' in affective disorder: a study of the tryptophan depletion test and relationships between peripheral and central serotonin indexes in citalopram-responders. *Acta Psychiatr Scand*. 1998;97:374-380.
540. Adams WR, Kiefer SW, Badia-Elder N. Tryptophan deficiency and alcohol consumption in rats as a model for disadvantaged human populations: a preliminary study. *Med Anthropol*. 1995;16:175-191.
541. Ahveninen J, Kahkonen S, Pennanen S et al. Tryptophan depletion effects on EEG and MEG responses suggest serotonergic modulation of auditory involuntary attention in humans. *Neuroimage*. 2002;16:1052-1061.

542. Ahveninen J, Jaaskelainen IP, Pennanen S et al. Auditory selective attention modulated by tryptophan depletion in humans. *Neurosci Lett*. 2003;340:181-184.
543. Akarte NR, Shastri NV. Studies on tryptophan-niacin metabolism in streptozotocin diabetic rats. *Diabetes*. 1974;23:977-981.
544. Anderson GH, Johnston JL. Nutrient control of brain neurotransmitter synthesis and function. *Can J Physiol Pharmacol*. 1983;61:271-281.
545. Anderson IM, Richell RA, Bradshaw CM. The effect of acute tryptophan depletion on probabilistic choice. *J Psychopharmacol*. 2003;17:3-7.
546. Angel-Meza AR, Gonzalez-Burgos I, Olvera-Cortes E et al. Chronic tryptophan restriction disrupts grooming chain completion in the rat. *Physiol Behav*. 1996;59:1099-1102.
547. Angel-Meza AR, Ramirez-Cortes L, Olvera-Cortes E et al. A tryptophan-deficient corn-based diet induces plastic responses in cerebellar cortex cells of rat offspring. *Int J Dev Neurosci*. 2001;19:447-453.
548. Angel-Meza AR, Ramirez-Cortes L, Adame-Gonzalez IG et al. Cerebral GABA release and GAD activity in protein- and tryptophan-restricted rats during development. *Int J Dev Neurosci*. 2002;20:47-54.
549. Anthony TG, Reiter AK, Anthony JC et al. Deficiency of dietary EAA preferentially inhibits mRNA translation of ribosomal proteins in liver of meal-fed rats. *Am J Physiol Endocrinol Metab*. 2001;281:E430-E439.
550. Aoyagi K, Oomura Y, Shimizu N. Concurrent measurement of serotonin metabolism and single neuron activity changes in the lateral hypothalamus of freely behaving rat. *Behav Brain Res*. 1992;49:205-212.
551. Aquilio E, Seri S. Effects of dietary changes on muricide activity in adult and young rats. *Boll Soc Ital Biol Sper*. 1983;59:717-722.
552. Arnulf I, Quintin P, Alvarez JC et al. Mid-morning tryptophan depletion delays REM sleep onset in healthy subjects. *Neuropsychopharmacology*. 2002;27:843-851.
553. Bach A. Oxaloacetate deficiency in MCT-induced ketogenesis. *Arch Int Physiol Biochim*. 1978;86:1133-1142.
554. Barbui C, Garattini S. Tryptophan and depression. *Lancet*. 1997;349:1553-1554.
555. Bel N, Artigas F. Reduction of serotonergic function in rat brain by tryptophan depletion: effects in control and fluvoxamine-treated rats. *J Neurochem*. 1996;67:669-676.
556. Bell C, Abrams J, Nutt D. Tryptophan depletion and its implications for psychiatry. *Br J Psychiatry*. 2001;178:399-405.
557. Benkelfat C, Ellenbogen MA, Dean P et al. Mood-lowering effect of tryptophan depletion. Enhanced susceptibility in young men at genetic risk for major affective disorders. *Arch Gen Psychiatry*. 1994;51:687-697.
558. Benkelfat C, Seletti B, Palmour RM et al. Tryptophan depletion in stable lithium-treated patients with bipolar disorder in remission. *Arch Gen Psychiatry*. 1995;52:154-156.
559. Benton D, Donohoe RT. The effects of nutrients on mood. *Public Health Nutr*. 1999;2:403-409.
560. Bjork JM, Dougherty DM, Moeller FG et al. The effects of tryptophan depletion and loading on laboratory aggression in men: time course and a food-restricted control. *Psychopharmacology (Berl)*. 1999;142:24-30.
561. Bjork JM, Dougherty DM, Moeller FG et al. Differential behavioral effects of plasma tryptophan depletion and loading in aggressive and nonaggressive men. *Neuropsychopharmacology*. 2000;22:357-369.

562. Bleiberg-Daniel F, Le Moullac B, Maire JC et al. Failure of tryptophan deficiency to reduce specifically serum levels of transthyretin or albumin in rats. *J Nutr.* 1990;120:1610-1616.
563. Booij L, Van der DW, Benkelfat C et al. Predictors of mood response to acute tryptophan depletion. A reanalysis. *Neuropsychopharmacology.* 2002;27:852-861.
564. Booth DA, French JA, Wainwright CJ et al. Personal benefits from post-ingestional actions of dietary constituents. *Proc Nutr Soc.* 1992;51:335-341.
565. Brown CM, Fletcher PJ, Coscina DV. Acute amino acid loads that deplete brain serotonin fail to alter behavior. *Pharmacol Biochem Behav.* 1998;59:115-121.
566. Burgund ED, Marsolek CJ, Luciana M. Serotonin levels influence patterns of repetition priming. *Neuropsychology.* 2003;17:161-170.
567. Byerley WF, Risch SC. Depression and serotonin metabolism: rationale for neurotransmitter precursor treatment. *J Clin Psychopharmacol.* 1985;5:191-206.
568. Calapai G, Corica F, Corsonello A et al. Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis. *J Clin Invest.* 1999;104:975-982.
569. Carew LB, Jr., Alster FA, Foss DC et al. Effect of a tryptophan deficiency on thyroid gland, growth hormone and testicular functions in chickens. *J Nutr.* 1983;113:1756-1765.
570. Carpenter LL, Anderson GM, Pelton GH et al. Tryptophan depletion during continuous CSF sampling in healthy human subjects. *Neuropsychopharmacology.* 1998;19:26-35.
571. Clancy JJ, Caldwell DF, Oberleas D et al. Effect of a chronic tryptophan dietary deficiency on the rat's sleep-wake cycle. *Brain Res Bull.* 1978;3:83-87.
572. Clark JA, Clark MS, Palfreyman ES et al. The effect of tryptophan and a tryptophan/5-hydroxytryptophan combination on indoles in the brains of rats fed a tryptophan deficient diet. *Psychopharmacologia.* 1975;45:183-188.
573. Cleare AJ, Bond AJ. Effects of alterations in plasma tryptophan levels on aggressive feelings. *Arch Gen Psychiatry.* 1994;51:1004-1005.
574. Cleare AJ, Bond AJ. Experimental evidence that the aggressive effect of tryptophan depletion is mediated via the 5-HT1A receptor. *Psychopharmacology (Berl).* 2000;147:439-441.
575. Clemens JA, Bennett DR, Fuller RW. The effect of a tryptophan-free diet on prolactin and corticosterone release by serotonergic stimuli. *Horm Metab Res.* 1980;12:35-38.
576. Delgado PL, Charney DS, Price LH et al. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. *Arch Gen Psychiatry.* 1990;47:411-418.
577. Delgado PL, Price LH, Miller HL et al. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. *Arch Gen Psychiatry.* 1994;51:865-874.
578. Delgado PL, Miller HL, Salomon RM et al. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. *Biol Psychiatry.* 1999;46:212-220.
579. Ellenbogen MA, Young SN, Dean P et al. Acute tryptophan depletion in healthy young women with a family history of major affective disorder. *Psychol Med.* 1999;29:35-46.
580. Feria-Velasco A, Del Angel AR, Gonzalez-Burgos I. Modification of dendritic development. *Prog Brain Res.* 2002;136:135-143.

581. Fernstrom JD, Hirsch NJ. Rapid repletion of brain serotonin in malnourished corn-fed rats following L-tryptophan injection. *Life Sci.* 1975;17:455-463.
582. Fernstrom JD, Hirsch MJ. Brain serotonin synthesis: reduction in corn-malnourished rats. *J Neurochem.* 1977;28:877-879.
583. Goddard AW, Sholomskas DE, Walton KE et al. Effects of tryptophan depletion in panic disorder. *Biol Psychiatry.* 1994;36:775-777.
584. Heninger GR, Delgado PL, Charney DS et al. Tryptophan-deficient diet and amino acid drink deplete plasma tryptophan and induce a relapse of depression in susceptible patients. *J Chem Neuroanat.* 1992;5:347-348.
585. Hughes JH, Ashton CH, Matthews D et al. Acute depletion of plasma tryptophan does not alter electrophysiological variables in healthy males. *Psychopharmacology (Berl).* 2000;152:119-121.
586. Huwig-Poppe C, Voderholzer U, Backhaus J et al. The tryptophan depletion test. Impact on sleep in healthy subjects and patients with obsessive-compulsive disorder. *Adv Exp Med Biol.* 1999;467:35-42.
587. Johnson L, El Khoury A, Aberg-Wistedt A et al. Tryptophan depletion in lithium-stabilized patients with affective disorder. *Int J Neuropsychopharmacol.* 2001;4:329-336.
588. Kahkonen S, Ahveninen J, Pennanen S et al. Serotonin modulates early cortical auditory processing in healthy subjects: evidence from MEG with acute tryptophan depletion. *Neuropsychopharmacology.* 2002;27:862-868.
589. Kahkonen S, Jaaskelainen IP, Pennanen S et al. Acute tryptophan depletion decreases intensity dependence of auditory evoked magnetic N1/P2 dipole source activity. *Psychopharmacology (Berl).* 2002;164:221-227.
590. Landolt HP, Kelsoe JR, Rapaport MH et al. Rapid tryptophan depletion reverses phenelzine-induced suppression of REM sleep. *J Sleep Res.* 2003;12:13-18.
591. Lehmann J. Tryptophan deficiency stupor--a new psychiatric syndrome. *Acta Psychiatr Scand Suppl.* 1982;300:1-57.
592. LeMarquand DG, Pihl RO, Young SN et al. Tryptophan depletion, executive functions, and disinhibition in aggressive, adolescent males. *Neuropsychopharmacology.* 1998;19:333-341.
593. McDougle CJ, Naylor ST, Cohen DJ et al. Effects of tryptophan depletion in drug-free adults with autistic disorder. *Arch Gen Psychiatry.* 1996;53:993-1000.
594. Murphy FC, Smith KA, Cowen PJ et al. The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers. *Psychopharmacology (Berl).* 2002;163:42-53.
595. Newhouse P, Tatro A, Naylor M et al. Alzheimer disease, serotonin systems, and tryptophan depletion. *Am J Geriatr Psychiatry.* 2002;10:483-484.
596. Norden M. Risk of tryptophan depletion following amino acid supplementation. *Arch Gen Psychiatry.* 1993;50:1000-1001.
597. Pant KC, Rogers QR, Harper AE. Plasma and tissue free amino acid concentrations in rats fed tryptophan-imbalanced diets with or without niacin. *J Nutr.* 1974;104:1584-1596.
598. Plaisant O, Leboyer M, Debray Q et al. [The concept of serotonergic depression]. *Ann Med Interne (Paris).* 1983;134:691-694.
599. Riedel WJ, Klaassen T, Deutz NE et al. Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. *Psychopharmacology (Berl).* 1999;141:362-369.
600. Riemann D, Feige B, Hornyak M et al. The tryptophan depletion test: impact on sleep in primary insomnia - a pilot study. *Psychiatry Res.* 2002;109:129-135.

601. Sahakian BJ, Wurtman RJ, Barr JK et al. Low tryptophan diet decreases brain serotonin and alters response to apomorphine. *Nature*. 1979;279:731-732.
602. Schmeck K, Sadigorsky S, Englert E et al. Mood changes following acute tryptophan depletion in healthy adults. *Psychopathology*. 2002;35:234-240.
603. Schwarz MJ, Offenbaecher M, Neumeister A et al. Evidence for an altered tryptophan metabolism in fibromyalgia. *Neurobiol Dis*. 2002;11:434-442.
604. Smeraldi E, Diaferia G, Erzegovesi S et al. Tryptophan depletion in obsessive-compulsive patients. *Biol Psychiatry*. 1996;40:398-402.
605. Smith KA, Fairburn CG, Cowen PJ. Relapse of depression after rapid depletion of tryptophan. *Lancet*. 1997;349:915-919.
606. Timiras PS, Hudson DB, Segall PE. Lifetime brain serotonin: regional effects of age and precursor availability. *Neurobiol Aging*. 1984;5:235-242.
607. Van Praag HM. Central monoamine metabolism in depressions. I. Serotonin and related compounds. *Compr Psychiatry*. 1980;21:30-43.
608. Walderhaug E, Lunde H, Nordvik JE et al. Lowering of serotonin by rapid tryptophan depletion increases impulsiveness in normal individuals. *Psychopharmacology (Berl)*. 2002;164:385-391.
609. Young SN, Tourjman SV, Teff KL et al. The effect of lowering plasma tryptophan on food selection in normal males. *Pharmacol Biochem Behav*. 1988;31:149-152.
610. Young SN, Ervin FR, Pihl RO et al. Biochemical aspects of tryptophan depletion in primates. *Psychopharmacology (Berl)*. 1989;98:508-511.
611. Zimmermann RC, McDougale CJ, Schumacher M et al. Effects of acute tryptophan depletion on nocturnal melatonin secretion in humans. *J Clin Endocrinol Metab*. 1993;76:1160-1164.
612. Ellenbogen MA, Young SN, Dean P et al. Acute tryptophan depletion in healthy young women with a family history of major affective disorder. *Psychol Med*. 1999;29:35-46.
613. Fernstrom JD, Hirsch NJ. Rapid repletion of brain serotonin in malnourished corn-fed rats following L-tryptophan injection. *Life Sci*. 1975;17:455-463.
614. Fernstrom JD, Hirsch MJ. Brain serotonin synthesis: reduction in corn-malnourished rats. *J Neurochem*. 1977;28:877-879.
615. Goddard AW, Sholomskas DE, Walton KE et al. Effects of tryptophan depletion in panic disorder. *Biol Psychiatry*. 1994;36:775-777.
616. Heninger GR, Delgado PL, Charney DS et al. Tryptophan-deficient diet and amino acid drink deplete plasma tryptophan and induce a relapse of depression in susceptible patients. *J Chem Neuroanat*. 1992;5:347-348.
617. Hughes JH, Ashton CH, Matthews D et al. Acute depletion of plasma tryptophan does not alter electrophysiological variables in healthy males. *Psychopharmacology (Berl)*. 2000;152:119-121.
618. Johnson L, El Khoury A, Aberg-Wistedt A et al. Tryptophan depletion in lithium-stabilized patients with affective disorder. *Int J Neuropsychopharmacol*. 2001;4:329-336.
619. Kahkonen S, Ahveninen J, Pennanen S et al. Serotonin modulates early cortical auditory processing in healthy subjects: evidence from MEG with acute tryptophan depletion. *Neuropsychopharmacology*. 2002;27:862-868.
620. Kahkonen S, Jaaskelainen IP, Pennanen S et al. Acute tryptophan depletion decreases intensity dependence of auditory evoked magnetic N1/P2 dipole source activity. *Psychopharmacology (Berl)*. 2002;164:221-227.

621. Landolt HP, Kelsoe JR, Rapaport MH et al. Rapid tryptophan depletion reverses phenelzine-induced suppression of REM sleep. *J Sleep Res.* 2003;12:13-18.
622. LeMarquand DG, Pihl RO, Young SN et al. Tryptophan depletion, executive functions, and disinhibition in aggressive, adolescent males. *Neuropsychopharmacology.* 1998;19:333-341.
623. McDougle CJ, Naylor ST, Cohen DJ et al. Effects of tryptophan depletion in drug-free adults with autistic disorder. *Arch Gen Psychiatry.* 1996;53:993-1000.
624. Murphy FC, Smith KA, Cowen PJ et al. The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers. *Psychopharmacology (Berl).* 2002;163:42-53.
625. Newhouse P, Tatro A, Naylor M et al. Alzheimer disease, serotonin systems, and tryptophan depletion. *Am J Geriatr Psychiatry.* 2002;10:483-484.
626. Norden M. Risk of tryptophan depletion following amino acid supplementation. *Arch Gen Psychiatry.* 1993;50:1000-1001.
627. Pant KC, Rogers QR, Harper AE. Plasma and tissue free amino acid concentrations in rats fed tryptophan-imbalanced diets with or without niacin. *J Nutr.* 1974;104:1584-1596.
628. Riedel WJ, Klaassen T, Deutz NE et al. Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation. *Psychopharmacology (Berl).* 1999;141:362-369.
629. Riemann D, Feige B, Hornyak M et al. The tryptophan depletion test: impact on sleep in primary insomnia - a pilot study. *Psychiatry Res.* 2002;109:129-135.
630. Sahakian BJ, Wurtman RJ, Barr JK et al. Low tryptophan diet decreases brain serotonin and alters response to apomorphine. *Nature.* 1979;279:731-732.
631. Schmeck K, Sadigorsky S, Englert E et al. Mood changes following acute tryptophan depletion in healthy adults. *Psychopathology.* 2002;35:234-240.
632. Schwarz MJ, Offenbaecher M, Neumeister A et al. Evidence for an altered tryptophan metabolism in fibromyalgia. *Neurobiol Dis.* 2002;11:434-442.
633. Smeraldi E, Diaferia G, Erzegovesi S et al. Tryptophan depletion in obsessive-compulsive patients. *Biol Psychiatry.* 1996;40:398-402.
634. Smith KA, Fairburn CG, Cowen PJ. Relapse of depression after rapid depletion of tryptophan. *Lancet.* 1997;349:915-919.
635. Van Praag HM. Central monoamine metabolism in depressions. I. Serotonin and related compounds. *Compr Psychiatry.* 1980;21:30-43.
636. Walderhaug E, Lunde H, Nordvik JE et al. Lowering of serotonin by rapid tryptophan depletion increases impulsiveness in normal individuals. *Psychopharmacology (Berl).* 2002;164:385-391.
637. Young SN, Tourjman SV, Teff KL et al. The effect of lowering plasma tryptophan on food selection in normal males. *Pharmacol Biochem Behav.* 1988;31:149-152.
638. Zimmermann RC, McDougle CJ, Schumacher M et al. Effects of acute tryptophan depletion on nocturnal melatonin secretion in humans. *J Clin Endocrinol Metab.* 1993;76:1160-1164.
639. Receptor physiology and hormone secretion in affective illness. *Psychopharmacol Bull.* 1983;19:479-495.
640. Bowers MB, Jr., Hartmann EL, Freedman DX. Sleep deprivation and brain acetylcholine. *Science.* 1966;153:1416-1417.
641. Brown DW. Abnormal fluctuations of acetylcholine and serotonin. *Med Hypotheses.* 1993;40:309-310.

642. Bryson G. Biogenic amines in normal and abnormal behavioral states. *Clin Chem*. 1971;17:5-26.
643. Conlay LA, Zeisel SH. Neurotransmitter precursors and brain function. *Neurosurgery*. 1982;10:524-529.
644. Erickson CK, Matchett JA. Correlation of brain amine changes with ethanol-induced sleep-time in mice. *Adv Exp Med Biol*. 1975;59:419-430.
645. Fernandez-Guardiola A, Escobar IA, Anton-Tay F et al. [Neurobiology of sleep]. *Bol Estud Med Biol*. 1973;28:41-70.
646. Fujita S, Ikezono K, Umezato M et al. General pharmacological properties of the main metabolite of flosequinan. *Arzneimittelforschung*. 1992;42:1212-1222.
647. Graves L, Pack A, Abel T. Sleep and memory: a molecular perspective. *Trends Neurosci*. 2001;24:237-243.
648. Kapen S, Fleming PD, Drachman DA. Cholinergic enhancement and REM sleep latency in the aged: lecithin does not reproduce physostigmine effect. *Neurology*. 1986;36:1079-1083.
649. Khateb A, Muhlethaler M, Alonso A et al. Cholinergic nucleus basalis neurons display the capacity for rhythmic bursting activity mediated by low-threshold calcium spikes. *Neuroscience*. 1992;51:489-494.
650. Kodama T, Takahashi Y, Honda Y. Enhancement of acetylcholine release during paradoxical sleep in the dorsal tegmental field of the cat brain stem. *Neurosci Lett*. 1990;114:277-282.
651. Leboyer M, Plaisant O. [Cholinergic hypothesis of depression]. *Encephale*. 1985;11:229-234.
652. Morgane PJ. Amine pathways and sleep regulation. *Brain Res Bull*. 1982;9:743-749.
653. Szymusiak R, McGinty D, Fairchild MD et al. Sleep-wake disturbances in an animal model of chronic cholinergic insufficiency. *Brain Res*. 1993;629:141-145.
654. Williams RH. Metabolism and mentation. *J Clin Endocrinol Metab*. 1970;31:461-479.
655. Wurtman RJ. When--and why--should nutritional state control neurotransmitter synthesis? *J Neural Transm Suppl*. 1979;69-79.
656. Francis KT, Hamrick ME, Smith RC. Drug metabolism in choline-deficient rats. *Res Commun Chem Pathol Pharmacol*. 1975;10:755-758.
657. Szymusiak R, McGinty D, Fairchild MD et al. Sleep-wake disturbances in an animal model of chronic cholinergic insufficiency. *Brain Res*. 1993;629:141-145.
658. Francis KT, Hamrick ME, Smith RC. Drug metabolism in choline-deficient rats. *Res Commun Chem Pathol Pharmacol*. 1975;10:755-758.
659. Szymusiak R, McGinty D, Fairchild MD et al. Sleep-wake disturbances in an animal model of chronic cholinergic insufficiency. *Brain Res*. 1993;629:141-145.
660. Blanloeil Y, Delaroche O, Tequi B et al. [Prolonged apnea after suxamethonium administration during staphylococcal toxic shock]. *Ann Fr Anesth Reanim*. 1996;15:189-191.
661. Byring RF, Pihko H, Tsujino A et al. Congenital myasthenic syndrome associated with episodic apnea and sudden infant death. *Neuromuscul Disord*. 2002;12:548-553.
662. Carrasco MS, Gomez AF, de Ory MJ et al. [Genetic study of plasma cholinesterases in the adult patients of the Cadiz region]. *Rev Esp Anesthesiol Reanim*. 1985;32:156-158.
663. Carrasco MS, Gomez AF, Gil C et al. [Family study of patients who have experienced succinylcholine apneas]. *Rev Esp Anesthesiol Reanim*. 1985;32:159-165.

664. Carrasco MS, Gomez AF, Gil C et al. [Presentation of a case of a silent genetic cholinesterase variant]. *Rev Esp Anesthesiol Reanim.* 1985;32:184-186.
665. Chautard-Freire-Maia EA, Carvalho RD, da Silva MC et al. Frequencies of atypical serum cholinesterase in a mixed population of northeastern Brazil. *Hum Hered.* 1984;34:364-370.
666. Chung SJ, Andrews D. Prolonged postoperative succinylcholine-induced apnea with pseudocholinesterase deficiency. *J Tenn Med Assoc.* 1982;75:535-536.
667. Cohen SN, Weber WW. Pharmacogenetics. *Pediatr Clin North Am.* 1972;19:21-36.
668. Cousin MT, Conseiller C, Guillosson JJ et al. [Serum pseudocholinesterases. Preliminary study]. *Anesth Analg (Paris).* 1974;31:651-663.
669. Davies P, Landy M. Suxamethonium and mivacurium sensitivity from pregnancy-induced plasma cholinesterase deficiency. *Anaesthesia.* 1998;53:1109-1111.
670. Deam D, Emmanuel ER. A family with the silent cholinesterase gene. *Anaesth Intensive Care.* 1983;11:259-260.
671. Epstein HM, Jarzemy D, Zuckerman L et al. Plasma cholinesterase activity in bank blood. *Anesth Analg.* 1980;59:211-214.
672. Frawley GP, Carden JR. Suxamethonium-induced prolonged apnoea in a premature neonate. *Anaesth Intensive Care.* 1994;22:192-194.
673. Gerosky T, O'Leary J, Hunt R et al. Prolonged apnea of an oral surgery patient after administration of succinylcholine. *J Oral Surg.* 1979;37:428-431.
674. Goedde HW, Kuriyama K. [Genetically determined variations in drug response (author's transl)]. *Tanpakushitsu Kakusan Koso.* 1975;20:539-548.
675. Goedde HW, Munsch H, Benkmann HG. [Succinylcholin sensitivity resulting from genetically determined serumcholinesterase variants]. *Prakt Anaesth.* 1976;11:339-346.
676. Goedde HW, Altland K. [Genetically dependent variability of drug effects]. *Med Klin.* 1970;65:1507-1517.
677. Ho VW, Osiovich H. A case of pseudocholinesterase deficiency in the neonate. *Am J Perinatol.* 1999;16:351-353.
678. Hutter CD. Succinylcholine-induced apnea. *Anesthesiology.* 1979;50:268.
679. Koseoglu V, Chiang J, Chan KW. Acquired pseudocholinesterase deficiency after high-dose cyclophosphamide. *Bone Marrow Transplant.* 1999;24:1367-1368.
680. Lang C, Lukasewitz P, Wulf H et al. [Plasma cholinesterase variations as a result of prolonged neuromuscular blockade. Review and problems encountered in two cases of prolonged neuromuscular blockade after muscle relaxation with succinylcholine as compared to mivacurium]. *Anaesthesist.* 2002;51:134-141.
681. Laxenaire MC, Vigneron C, Petry T et al. [Delay of decurarization related to pseudocholinesterase deficiency]. *Anesth Analg (Paris).* 1977;34:61-67.
682. Lemaire WJ, Nagel EL, Smith JC. Plasma cholinesterase deficiency. A possible complication during anesthesia. *Obstet Gynecol.* 1972;39:552-555.
683. Lindsay PA, Lumley J. Suxamethonium apnoea masked by tetrahydroaminacrine. *Anaesthesia.* 1978;33:620-622.
684. Mogensen JV, Hanel HK. [A Danish cholinesterase card index]. *Ugeskr Laeger.* 1976;138:2367-2372.

685. Ohno K, Tsujino A, Brengman JM et al. Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. *Proc Natl Acad Sci U S A*. 2001;98:2017-2022.
686. Pasquariello CA, Schwartz RE. Plasma cholinesterase deficiency in a neonate. *Can J Anaesth*. 1993;40:529-531.
687. Pasquariello CA, Schwartz RE. Plasma cholinesterase deficiency in a neonate: a follow-up. *Can J Anaesth*. 1995;42:364.
688. Pembrey ME. Pharmacogenetics. *Practitioner*. 1974;213:647-654.
689. Perianes FE, Alonso AP, Garcia Simon MN et al. [Genetic study in an extensive family group of a patient suffering from prolonged succinylcholine apnea]. *Rev Esp Anesthesiol Reanim*. 1988;35:329-332.
690. Pronk IR, van der Wal SJ, The TH. [Familial examinations for the presence of atypical cholinesterase]. *Ned Tijdschr Geneesk*. 1975;119:1544-1547.
691. Roux A, Ansermino JM. Plasma cholinesterase deficiency in a premature neonate. *Can J Anaesth*. 1994;41:263.
692. Simon NM, Del Greco F, Dietz AA et al. Serum cholinesterase deficiency in renal failure. *Trans Am Soc Artif Intern Organs*. 1969;15:328-332.
693. Smith DC, Ridley SA, Donaldson KF. Fresh frozen plasma and edrophonium in a patient with a plasma cholinesterase deficiency. *Anaesthesia*. 1993;48:511-513.
694. Valle SJ, Herraiz D, V, Gracia VC et al. [Succinylcholinic apnoea, study of a thirteen-member family (author's transl)]. *Rev Esp Anesthesiol Reanim*. 1982;29:42-43.
695. Vardi J, Flechter S, Tupilsky M et al. Kleine-Levin syndrome with periodic apnea during hypersomnic stages--E.E.G. study. *J Neural Transm*. 1978;43:121-132.
696. Vardi J, Flechter S, Tupilsky M et al. Kleine-Levin syndrome with periodic apnea during hypersomnic stages--E.E.G. study. *J Neural Transm*. 1978;43:121-132.
697. Vassallo SA, Goudsouzian NG. Plasma cholinesterase activity in infants. *Can J Anaesth*. 1994;41:654-655.
698. Viby-Mogensen J, Hanel HK. Prolonged apnoea after suxamethonium: an analysis of the first 225 cases reported to the Danish Cholinesterase Research Unit. *Acta Anaesthesiol Scand*. 1978;22:371-380.
699. Yen T, Nightingale BN, Burns JC et al. Butyrylcholinesterase (BCHE) genotyping for post-succinylcholine apnea in an Australian population. *Clin Chem*. 2003;49:1297-1308.
700. Zsigmond EK, Eilderton TE. Survey of local anesthetic toxicity in the families of patients with atypical plasma cholinesterase. *J Oral Surg*. 1975;33:833-837.
701. Byring RF, Pihko H, Tsujino A et al. Congenital myasthenic syndrome associated with episodic apnea and sudden infant death. *Neuromuscul Disord*. 2002;12:548-553.
702. Carrasco MS, Gomez AF, de Ory MJ et al. [Genetic study of plasma cholinesterases in the adult patients of the Cadiz region]. *Rev Esp Anesthesiol Reanim*. 1985;32:156-158.
703. Carrasco MS, Gomez AF, Gil C et al. [Family study of patients who have experienced succinylcholine apneas]. *Rev Esp Anesthesiol Reanim*. 1985;32:159-165.
704. Carrasco MS, Gomez AF, Gil C et al. [Presentation of a case of a silent genetic cholinesterase variant]. *Rev Esp Anesthesiol Reanim*. 1985;32:184-186.
705. Chung SJ, Andrews D. Prolonged postoperative succinylcholine-induced apnea with pseudocholinesterase deficiency. *J Tenn Med Assoc*. 1982;75:535-536.

706. Cohen SN, Weber WW. Pharmacogenetics. *Pediatr Clin North Am.* 1972;19:21-36.
707. Cousin MT, Conseiller C, Guillosson JJ et al. [Serum pseudocholinesterases. Preliminary study]. *Anesth Analg (Paris)*. 1974;31:651-663.
708. Davies P, Landy M. Suxamethonium and mivacurium sensitivity from pregnancy-induced plasma cholinesterase deficiency. *Anaesthesia*. 1998;53:1109-1111.
709. Deam D, Emmanuel ER. A family with the silent cholinesterase gene. *Anaesth Intensive Care*. 1983;11:259-260.
710. Epstein HM, Jarzemy D, Zuckerman L et al. Plasma cholinesterase activity in bank blood. *Anesth Analg*. 1980;59:211-214.
711. Frawley GP, Carden JR. Suxamethonium-induced prolonged apnoea in a premature neonate. *Anaesth Intensive Care*. 1994;22:192-194.
712. Gerosky T, O'Leary J, Hunt R et al. Prolonged apnea of an oral surgery patient after administration of succinylcholine. *J Oral Surg*. 1979;37:428-431.
713. Goedde HW, Kuriyama K. [Genetically determined variations in drug response (author's transl)]. *Tanpakushitsu Kakusan Koso*. 1975;20:539-548.
714. Goedde HW, Munsch H, Benkmann HG. [Succinylcholin sensitivity resulting from genetically determined serumcholinesterase variants]. *Prakt Anaesth*. 1976;11:339-346.
715. Goedde HW, Altland K. [Genetically dependent variability of drug effects]. *Med Klin*. 1970;65:1507-1517.
716. Hutter CD. Succinylcholine-induced apnea. *Anesthesiology*. 1979;50:268.
717. Koseoglu V, Chiang J, Chan KW. Acquired pseudocholinesterase deficiency after high-dose cyclophosphamide. *Bone Marrow Transplant*. 1999;24:1367-1368.
718. Lang C, Lukasewitz P, Wulf H et al. [Plasma cholinesterase variations as a result of prolonged neuromuscular blockade. Review and problems encountered in two cases of prolonged neuromuscular blockade after muscle relaxation with succinylcholine as compared to mivacurium]. *Anaesthesist*. 2002;51:134-141.
719. Laxenaire MC, Vigneron C, Petry T et al. [Delay of decurarization related to pseudocholinesterase deficiency]. *Anesth Analg (Paris)*. 1977;34:61-67.
720. Lemaire WJ, Nagel EL, Smith JC. Plasma cholinesterase deficiency. A possible complication during anesthesia. *Obstet Gynecol*. 1972;39:552-555.
721. Lindsay PA, Lumley J. Suxamethonium apnoea masked by tetrahydroaminacrine. *Anaesthesia*. 1978;33:620-622.
722. Mogensen JV, Hanel HK. [A Danish cholinesterase card index]. *Ugeskr Laeger*. 1976;138:2367-2372.
723. Ohno K, Tsujino A, Brengman JM et al. Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. *Proc Natl Acad Sci U S A*. 2001;98:2017-2022.
724. Pasquariello CA, Schwartz RE. Plasma cholinesterase deficiency in a neonate. *Can J Anaesth*. 1993;40:529-531.
725. Pasquariello CA, Schwartz RE. Plasma cholinesterase deficiency in a neonate: a follow-up. *Can J Anaesth*. 1995;42:364.
726. Pembrey ME. Pharmacogenetics. *Practitioner*. 1974;213:647-654.

727. Perianes FE, Alonso AP, Garcia Simon MN et al. [Genetic study in an extensive family group of a patient suffering from prolonged succinylcholine apnea]. *Rev Esp Anesthesiol Reanim.* 1988;35:329-332.
728. Pronk IR, van der Wal SJ, The TH. [Familial examinations for the presence of atypical cholinesterase]. *Ned Tijdschr Geneeskd.* 1975;119:1544-1547.
729. Roux A, Ansermino JM. Plasma cholinesterase deficiency in a premature neonate. *Can J Anaesth.* 1994;41:263.
730. Smith DC, Ridley SA, Donaldson KF. Fresh frozen plasma and edrophonium in a patient with a plasma cholinesterase deficiency. *Anaesthesia.* 1993;48:511-513.
731. Valle SJ, Herraiz D, V, Gracia VC et al. [Succinylcholinic apnoea, study of a thirteen-member family (author's transl)]. *Rev Esp Anesthesiol Reanim.* 1982;29:42-43.
732. Vassallo SA, Goudsouzian NG. Plasma cholinesterase activity in infants. *Can J Anaesth.* 1994;41:654-655.
733. Yen T, Nightingale BN, Burns JC et al. Butyrylcholinesterase (BCHE) genotyping for post-succinylcholine apnea in an Australian population. *Clin Chem.* 2003;49:1297-1308.
734. Zsigmond EK, Eilderton TE. Survey of local anesthetic toxicity in the families of patients with atypical plasma cholinesterase. *J Oral Surg.* 1975;33:833-837.